Managed medical information exchange

Information

  • Patent Grant
  • 11367533
  • Patent Number
    11,367,533
  • Date Filed
    Monday, June 29, 2015
    9 years ago
  • Date Issued
    Tuesday, June 21, 2022
    2 years ago
Abstract
Management of medical information including collection of medical information from a data source, redaction of at least a portion of the medical records, and/or formatting the medical information for access by users. Accordingly, exchange of medical information may be facilitated, for example, to facilitate data analytics by internal users and/or one or more external entities. The medical information may have patient identifying information and/or protected health information (PHI) removed therefrom prior to being stored in a shareable data portion for access by users. Further still, the medical information in the shareable data portion may be formatted according to an identity of a user accessing the data, a context in which the data is to be used, and/or a requested format of the data. In turn, the exchange of medical information may facilitate data analytics that may serve a variety of beneficial purposes.
Description
BACKGROUND

Many healthcare facilities utilize pharmacy resources to prepare medication preparations that are to be administered to a patient. Such pharmacy resources may be located locally at the healthcare facility or may be remote from the healthcare facility. In either regard, medication preparations at the pharmacy resource may be prepared in response to receipt of a medication dose order. Such medication dose orders may be, in at least some instances, patient-specific dose orders that are generated by a healthcare professional and correspond to a request for preparation of the medication preparation to be prepared for administration to the patient. In other applications, the dose orders may be stock orders or non-patient-specific.


Many healthcare facilities generate records corresponding to dose orders that are prepared by a pharmacy resource. The records may include information received with the medical dose order and/or information that may be added to the record by the pharmacy resource (e.g., including details about the products and/or preparation used to prepare the dose corresponding to the medical dose order). Such records may be stored and/or used locally at the pharmacy resource for a variety of potential purposes including for example, regulatory compliance, patient safety, inventory management, staffing decisions, or other purposes related to the management of the pharmacy resource and/or medication preparations.


Furthermore, continued developments in communication technology and collaborative tools increasingly make it easier to share and access data in a networked environment (e.g., through software services, data sharing platforms, or other network connectivity sometimes collectively referred to as “cloud services”). However, medical information (e.g., including dose order records or the like) may be subjected to access and/or dissemination restrictions. For example, access to such data may be limited to access by appropriate personnel at the healthcare facility or pharmacy resource. For instance, in the United States the Health Insurance Portability and Accountability Act (HIPAA) provides regulatory requirements regarding the handling, dissemination, or other privacy related aspects of medical records that may contain protected health information (PHI). In this regard, the use, dissemination, and/or access to dose order records, and especially patient-specific dose order records that may include PHI may be limited by regulatory compliance and/or other privacy concerns. As such, despite the benefits that may be provided with the ability to collaboratively share data for application of cloud services thereto, limits on the use of data may limit the access to such valuable data.


Furthermore, systems used to maintain and/or generate medical information may be proprietary, such that specific data formats are utilized. Thus data exchange may be limited by data formatting limitations. For instance, data generated or stored in a proprietary format specific to a first entity may not be readable by another entity.


SUMMARY

The present disclosure relates to systems and methods that facilitate collaborative approaches to the management of information, particularly, information related to medication preparation information received in relation to provision of medical care. In this regard, the present disclosure relates to managed exchange of medical information. The exchange of medical information may be improved by use of selective redaction and/or formatting of the medical information. For example, to allow for increased exchange of medical information that may include patient identifying information or protected health information (PHI), certain data of the medical information may be redacted. Furthermore, a cryptographic hash function may be applied that reliably transforms a portion of information (e.g., information related to patient identifier) into a non-identifying value. In turn, records may still be associated with a given patient while the patient's PHI and/or patient identifying information may be removed.


Furthermore, given the potentially wide array of data analytics that may be applied to medical information exchanged using the description presented herein, the data may be formatted prior to access by users of a data exchange platform to facilitate specific data analytics. This may include a standardized format that is common to all users of the system and/or particularized formats corresponding to particular users, particular uses of the data, and/or particular types of data. In any regard, the use of an exchange platform as described herein may facilitate improved access to data to allow for more expanded, robust, and efficient data analytics in a number of contexts. In particular, inter-party exchange of data may be improved through data formatting rules associated with a collaboration system described herein. As such, data analytics may be expanded as data from a plurality of sources may be utilized and provided in a format. For example, data analytics related to multiple, inter-party data sources may be facilitated by the disclosure presented herein may help improve patient safety (e.g., by identifying potentially harmful trends with a collection of data), provide business intelligence, assist in reducing the cost of healthcare, or other meaningful benefits.


Accordingly, a first aspect includes a system for exchange of information related to patient-specific medication preparations. The system includes a data storage device in operative communication with one or more healthcare facilities to receive, from the one or more healthcare facilities, information regarding patient-specific medication preparations prepared at corresponding respective ones of the one or more healthcare facilities. In embodiments, the medical information may also include non-patient specific data received from one or more additional sources. The data storage device includes a sharable data portion that stores redacted data records having patient identifying (e.g., protected health information (PHI)) removed therefrom. The redacted records correspond to the information regarding medication preparations that is received from the one or more healthcare facilities. The system also includes a collaboration module that is in operative communication with the data storage device. The collaboration module is operative to access the shareable data portion to extract data from the shareable data portion, transform the extracted data into a data format based at least in part on a predetermined operational need, and load the formatted data into a remotely accessible data storage location that is accessible remotely from the data storage device. In this regard, the predetermined operational need may be based on an identified data analysis to be performed, an identity of a party accessing the data, a requested format by a party accessing the data, or some other particular purpose for the data.


A number of feature refinements and additional features are applicable to the first aspect. These feature refinements and additional features may be used individually or in any combination. As such, each of the following features that will be discussed may be, but are not required to be, used with any other feature or combination of features of the first aspect.


For example, the PHI may include a patient identifier. Furthermore, the system of the first aspect may facilitate removal of patient identifying information, while still allowing an association between data records and a given patient. As such, one or more of the redacted data records stored in the shareable data portion may also comprise a unique identifier that associates one or more portions of the information regarding medication preparations to a given patient without providing identifying characteristics relative to the patient. The unique identifier may include a hash value generated in response to application of a hash function to the patient identifier.


The hash function may be executed by a processor at the data storage device to generate the redacted data records that are stored in the shareable data portion. Alternatively, a hash function may be executed locally at the one or more healthcare facilities to remove patient identifying information prior to providing the data to the data storage device. Accordingly, the system may receive medical information that has been redacted at a data source. As such, the hash function may be executed by a processor at the one or more healthcare facilities to generate the redacted data records that are received at the central storage server for storage in the sharable data portion. In an embodiment, the hash value may include a deterministic, non-invertable value based on the patient identifier. That is, for each given unique patient identifier used to generate a has value, a corresponding unique hash value is generated. Furthermore, a user may not be able to ascertain the plain text patient identifier using only the hash function.


In an embodiment, the data storage device may also include a backup data portion that comprises complete data records (i.e., that potentially includes PHI) corresponding to at least a portion of the information regarding medication preparations received from the one or more healthcare facilities. The backup data portion and the shareable data portion may be separately accessible on the data storage device. That is, users who access the shareable data portion may not have access to the backup data portion. The collaboration module may provide a plurality of users selective and secure access to the shareable data portion based on a plurality of security layers applied to access the shareable data portion.


In an embodiment, the data format in which the collaboration module provides the redacted data may include a standardized data format accessible by the plurality of users. The data format may include a plurality of distinct data formats. As such, different ones of the plurality of distinct data formats may be accessible by corresponding different respective ones of the plurality of users.


In an embodiment, the data storage device may include a data storage server located remotely from the one or more healthcare facilities. Specifically, the data storage device may comprise a plurality of mirrored data servers distributed at distinct geographic locations. As such, redundancy may be provided such that the likelihood of data loss at both of the distributed data servers is reduced.


In an embodiment, the system of the first aspect may be used in connection with the ordering, preparation, and/or administration of a dose to a patient. As such, the information regarding medication preparations may include dose order records generated in response to received dose orders for mediation preparations to be administered to a patient.


The system of the first aspect may also include an analytics module in operative communication with the data storage location to retrieve the formatted data. In turn, the analytics module may be operative to perform at least one analysis on the information regarding medication preparations in relation to a specific given patient without the particular identity of the specific given patient. The analysis performed by the data analytics module may at least include analysis with respect to the unique patient identifier. For instance, doses administered to a given patient may be analyzed.


Other analysis may be facilitated or conducted without limitation. Examples of such analysis may include error tracking in relation to one or more given dose order data fields. Accordingly, tracked errors may be examined to determine if a common data parameter exists to facilitate a root cause investigation. For example, high error rates with respect to doses prepared with a given drug or medical product may allow for underlying causes (e.g., a potential confusing label or the like) to be identified with respect to the given drug or medical product.


Further still, data analysis may be facilitated or performed to help parameterize and evaluate a supply chain related to the manufacture, ordering, preparation, distribution, and/or administration of a dose. In this regard, as data related to a given dose, including medical product information used in the preparation of the dose, may be provided to the system, inventory tracking and supply chain evaluation may be conducted at any one or more portions of the supply chain from, for example, a medical product manufacturer to, for example, dose administration. Such analysis may be at least partially based on one or more dose order data fields contained in the medical information received at the system.


In an embodiment, the information regarding medication preparations may be received at the data storage device in accord with a local data policy of each respective one of the one or more healthcare facilities. As such and as stated above, patient identifying information may be removed from the medical information prior to the receipt of the data at the system of the first aspect. The removal of such patient identifiers may be at least in part based on the local data policy of each respective healthcare facility. The local data policy may be configurable for each respective one of the healthcare-facilities.


A second aspect includes a method for generation of shareable information regarding patient-specific medication preparations. The method includes receiving, from one or more healthcare facilities, information regarding patient-specific medication preparations prepared at corresponding respective ones of the one or more healthcare facilities for administration to a patient. The method further includes storing the information as a shareable data portion stored on a data storage device in the form of redacted data records that correspond to the information regarding patient-specific medication preparations that is received from the one or more healthcare facilities. The redacted records have patient identifying information (e.g., protected healthcare information (PHI)) removed therefrom. The method further includes formatting the redacted data records to a format corresponding with a predetermined operational need and loading the formatted data into a remotely accessible storage location for access by users remote from the storage location.


A number of feature refinements and additional features are applicable to the second aspect. These feature refinements and additional features may be used individually or in any combination. As such, each of the following features that will be discussed may be, but are not required to be, used with any other feature or combination of features of the second aspect. Furthermore, any one or more of the feature refinements and additional features described above in relation to the first aspect may be, but are not required to be, used with the second aspect.


For instance, in an embodiment, the PHI may include at least a patient identifier. The method may further include associating a unique identifier with one or more of the redacted data records that corresponds to a given patient and does not provide identifying capability relative to the patient. As such, the storing may further include applying a hash function to the patient identifier and generating the unique identifier in response to the applying. The unique identifier may, in turn, comprise a hash value resulting from the applying.


In an embodiment, the method may further include providing a plurality of users selective and secure access to the redacted data records. For instance, to access the redacted data records, a user may be required to undergo a plurality of security layers that may require provision of authentication information.


In an embodiment, the formatting may include formatting the redacted data records to a standardized format accessible by the plurality of users. Additionally or alternatively, the formatting may include formatting the redacted data records to a plurality of distinct data formats. The different ones of the plurality of distinct data formats may be accessible by corresponding different respective ones of the plurality of users.


In an embodiment, the method may further include generating the information regarding medication preparations comprise dose order records in response to received dose orders for mediation preparations to be administered to a patient. The method may also include accessing the data storage location to retrieve the formatted data and analyzing the information regarding medication preparations in relation to a specific given patient without the particular identity of the specific given patient. The method may include performing any one or more of the types of analysis described above in relation to the first aspect.


Additionally, the method may further include that the receiving the information regarding medication preparations is at least partially based on a local data policy of each respective one of the one or more healthcare facilities. As such and as described above, a local data policy may be enforced at the healthcare facility.


While the foregoing has referenced receiving medical information from a healthcare facility, the foregoing system and method aspects may also be utilized to receive medical information from any one or more of a plurality of data sources. Such data sources may include pharmaceutical manufacturers that manufacture drug products or medical products (e.g., that may be used in the preparation of a dose). The data sources may also include hospital information systems. Hospital information systems may provide data related to inventory tracking of medical products received and/or distributed throughout a facility. The hospital information systems may also provide medical information including medical records or the like. Additional data sources may include, for example, information from medical device operational databases (e.g., including administration devices such as infusion pumps) and/or dispensing cabinets. Furthermore, any one or more of the data sources may, but are not required to, access data for purposes of performing data analytics or the like. Accordingly, data analytics on aggregated data received from a number of sources may be facilitated. In this regard, data originating from a plurality of sources in connection with the manufacture, ordering, preparation, and/or administration of a dose may be aggregated to provide a wider array of analytical options in relation to the data. The improved access to such aggregated, redacted, and formatted data may facilitate improvements in a number of contexts including patient safety, pharmacy efficiency, business development, inventory management, and others.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic view of an embodiment of a system for exchange of information related to medication preparations.



FIG. 2 is a schematic view of an embodiment of a system for exchange of information related to medication preparations.



FIG. 3 is a schematic view of an embodiment of a collaboration platform with collaborative data analytics relative to shared information related to medication preparations.



FIG. 4 is a flow chart depicting an embodiment of a method for exchange of information related to medication preparations.



FIG. 5 is a schematic view of an embodiment of an implementation of a collaboration platform for exchange of medical information in a particular context including dose preparation and administration.





DETAILED DESCRIPTION

The following description is not intended to limit the invention to the forms disclosed herein. Consequently, variations and modifications commensurate with the following teachings, skill and knowledge of the relevant art, are within the scope of the present invention. The embodiments described herein are further intended to explain modes known of practicing the invention and to enable others skilled in the art to utilize the invention in such, or other embodiments and with various modifications required by the particular applications(s) or use(s) of the present invention.


The present disclosure generally relates to the exchange of medical information, and especially to the management of the exchange of medical information that may include dose order records related to medication preparations prepared for administration to a patient for the purpose of providing data analytics relative to the medical information. The exchange of such medical information may facilitate a data collaboration platform that enables various entities to perform data analytics on the medical information that may originate from a plurality of data sources for a variety of purposed including, for example, to improve patient safety, to track medical trends, to obtain business intelligence, or for other purposes related to the medical information.


Different entities may have the incentive and/or know-how to provide different kinds of analytics. Accordingly, the present disclosure facilitates a collaboration platform that enables widespread sharing of data to a plurality of parties that may each provide data analytics. In turn, providing a data collaboration platform that provides collected and/or aggregated data in an appropriate format to a plurality of potentially unrelated parties may facilitate improved data analytics based on the variety of providers that may access and/or analyze the formatted data that is provided by the platform.


Accordingly, the platform may be facilitated by a collaboration system that includes at least one data storage device comprising a backup data portion and a shareable data portion. The collaboration system may further include a collaboration module. In this regard, the collaboration system may receive medical information from plurality of data sources. Additionally, the collaboration system may provide access to a plurality of users that access the collaboration system and receive data (e.g., for the purpose of performing data analytics). A party comprising a data source may additionally comprise a party that accesses the collaboration system to access data for the purpose of data analytics. That is, a party (e.g., an individual user, a corporate user, a governmental user, or the like) providing data to the collaboration system may further retrieve data from the collaboration system that includes the data supplied by the party and/or data from other parties that has been aggregated.


A particular concern regarding exchange of medical information includes maintaining the privacy of patients as it relates to the exchange of medical information. For instance, medical information may include patient identifying information (e.g., potentially including protected health information (PHI)). In this regard, dissemination of medical information may subject to restrictions due to regulatory issues (e.g., the Health Insurance Portability and Accountability Act (HIPAA) in the United States may prohibit dissemination of medical information with PHI) or other privacy concerns. Accordingly, the embodiments described herein may be operative to redact medical information to remove patient identifying information (e.g., PHI) from the data.


While removal of PHI or other patient identifying information may be necessary prior to dissemination of medical information for compliance with regulations such as HIPAA or for other privacy factors, it may still be beneficial to associate related medical records to a given patient, even if the identity of a patient is not provided. For instance, if a patient named “Jane Doe” may have a number of medical information records associated with her. The present disclosure facilitates redaction of those medical information records by use of a unique identifier. For instance, Jane Doe's medical records may be associated with “Patient X,” where Patient X is non-identifying of Jane Doe. As such, some data analytics may benefit from a non-identifying association between medical records and a given patient (e.g., analytics that relate to trends relative to given patients or analytics that relate to correlations with specific patients). For purposes of these analytics, simply identifying related medical records for a given patient, even in the absence of identifying information regarding the patient may be beneficial. As such, the embodiments described herein may provide such a unique identifier that may associate medical information for a given patient, but not provide any patient identifying information. For instance, a patient identifier may be used as an input to a one-way cryptographic hash function that generates a hash value that may comprise the unique identifier. In this regard, each unique patient identifier may result in a corresponding unique hash value that does not identify the patient when input to the hash function. As such, the unique identifier (e.g., the hash value) may be used to associate medical information to a given patient without providing patient identification.


As such, a collaboration platform facilitated by the embodiments herein may generate and/or store redacted medical information. A collaboration platform may further provide access to formatted data generated from redacted data records to facilitate data analytics. In turn, the format provided may be a standardized format that is common to all users or may include specialized or particular formats (e.g., proprietary formats) that are based on a user, application, or other criteria. In any regard, the platform described herein including the system and methods described below facilitate improved data sharing to promote application of cloud services and other data analytics to medical information for a variety of purposes.



FIG. 1 depicts an embodiment of a system 100 that facilitates exchange of medical information. In an application, the medical information may include information regarding medication preparations prepared in response to a dose order. For example, a healthcare facility 110 may utilize a local or remote pharmacy resource that is capable of preparing a medication preparation (also referred to herein as a dose) for administration to a patient. In this regard, a plurality of healthcare facilities 110a, 110b, and 110c may be in operative communication with a data storage device 120. While three healthcare facilities 110a-110c are depicted in FIG. 1, fewer or more healthcare facilities 110 may be in operative communication with the data storage device 120 without limitation.


The healthcare facilities 110a-110c depicted in FIG. 1 may correspond to any appropriate healthcare facility 110 that generates, stores, supplements, or accesses medical information. Accordingly, the healthcare facilities 110 may include but are not limited to hospitals, pharmacies, outpatient care providers, home care providers, or the like. In any regard, the information provided to the data storage device 120 may include any medical information. In an embodiment, the medical information may relate to medication preparations such as doses to be administered to a patient that are prepared in response to a dose order. In a particular embodiment, the medical information may include patient-specific records corresponding to medication preparations (i.e., doses) that the healthcare facility 110 prepared and/or requested to be prepared for administration to a patient. As such, the healthcare facilities 110 may have access to pharmacy resources that may be utilized to prepare medications for administration to a patient. Access to pharmacy resources may include use of a local pharmacy located at the healthcare facility or use of remote pharmacy that provides medical information (e.g., dose order records) and medication preparations to the healthcare facility 110. For example, at least a portion of the healthcare facilities 110 may include hospital facilities that may include local pharmacy resources that generate dose order records in response to receipt of dose orders that correspond to requested medication preparations.


In this regard, the healthcare facility 110 may utilize a pharmacy workflow manager to generate and/or supplement the medical information that is to be provided to the data storage device 120. This pharmacy workflow manager may include any or all details as described in U.S. application Ser. No. 14/022,415, which is incorporated by reference in its entirety. An example of one such pharmacy workflow manager may include the DoseEdge™ pharmacy workflow manager offered by Baxter Healthcare Corporation of Deerfield, Ill. In this regard, the healthcare facility 110 may employ a tool that may capture dose order information to generate and/or supplement dose order records corresponding to a dose to be prepared for administration to the patient. This may include capturing dose order data received from an order entry system and/or supplementing the dose order record with dose order metadata regarding the dose to be prepared and/or the preparation of the dose. As described in greater detail below, the dose order records may comprise medical information that may be provided to the data storage device 120.


In turn, the data storage device 120 may be operative to store the information regarding the medication preparations such as, for example, dose order records received from the healthcare facility 110. In this regard, the healthcare facility 110 may provide a dose order record that corresponds to a dose order received from a healthcare provider. One example may be a dose order record generated in response to a provider generating a dose order that is received at a pharmacy for a medication dose to be administered to a patient. Upon receipt of the dose order, the healthcare facility 110 may generate a dose order record corresponding to the dose order.


The dose order record may contain one or more dose order record data fields. The dose order record data fields may be populated with dose order metadata related to the dose order. The dose order metadata may be obtained from a received dose order (e.g., by way of a dose order entry system or the like) or may be associated with the dose order after receipt of the dose order (e.g., by a pharmacy workflow manager or the like during the management, preparation, and/or distribution of the dose corresponding to the dose order). The dose order record data fields may include one or more fields that provide patient identifying information. For instance, the dose order record data fields may include data related to a patient name, geographic data, pertinent dates (e.g., date of birth, date of admission, date of administration, etc.), telephone numbers, fax numbers, email addresses, social security numbers, medical record numbers, health plan beneficiary numbers, account numbers, certificate/license numbers, vehicle identifiers and serial numbers including license plate numbers, device identifiers and serial numbers, uniform resource locators (URLs), Internet protocol addresses, biometric identifiers (i.e. retinal scan, fingerprints), identifying images, or any unique identifying number, characteristic or code. The patient identifier may, in this regard, comprise PHI that is associated with a dose order record.


Other potential dose order record data fields may also be provided that relate to the generation, preparation, distribution, and/or administration of the dose. For instance, such dose order record data fields may include, for instance, a scheduled drug administration date/time, an actual drug administration date/time, a scheduled distribution date/time, an actual distribution date/time, an expiration date for the medication preparation, a dilution value, a count of the number of medical products in the dose, a date/time of entry of the dose order, a volume measure of the dose, a date/time of the first dose of a series of doses, an indicator as to whether the dose is a first dose in a series of doses, an indicator of whether the dose comprises hazardous materials, an indicator of whether the dose is a high risk dose, a dose identifier, an indication of whether the dose is a test dose, a label format for a label corresponding to the dose, a nursing unit corresponding to the dose, order instructions, whether the dose order is on hold, a date/time for when the dose order is to be on hold, an overfill amount for the dose, a basal energy expenditure value for a patient, a body surface area value for a patient, a patient height, a patient weight, a duration for how long a dose is pending, a date/time the dose was prepared, whether a label for the dose order has been printed, at what time the dose order label was printed, the name of the printer to which the dose order label was printed, a rate of administration of the dose, an indication of whether the dose was ever rejected by a pharmacist during preparation, a date/time the dose was rejected, the identity of the pharmacist that rejected the dose, an administration route for the dose, a history of scan events for the dose, a date/time of scan events for the dose, a date/time the dose was sorted, an indication of the dose status, an indication of whether the dose was a stock dose, whether the dose was for total parenteral nutrition (TPN), an indication of the type of TPN associated with the dose, a date/time the dose was verified by a pharmacist, an identify of who verified the dose, an indication of who performed a given step related to the dose, dose preparation documentation (e.g., including images of the dose preparation and/or product preparation for components of the dose order), an error log for the dose or other appropriate information related to the dose. In an embodiment, the dose order record including any one or more of the fields described above may be provided to the data storage device 120.


The data storage device 120 may be located remotely from each healthcare facility 110 with which the data storage device 120 is in communication. In an embodiment, the information received at the data storage device 120 may be a complete data record received from a healthcare facility 110. A complete data record may refer to a data record that contains the same information when received at the data storage device 120 as was contained by the data record at the healthcare facility 110. That is, a complete data record may have no data redacted therefrom. The information received at the data storage device 120 may be dose order records with information related to one or more dose order record fields as described above. Accordingly, the data storage device 120 may thus store a backup copy of the records provided from each respective healthcare facility 110. That is, complete copies of dose order records from the healthcare facility 110 may be provided to and stored on the data storage device 120. Accordingly, the data storage device 120 may include a backup portion 130 that stores the complete data records (e.g., dose order records) received from each respective one of the healthcare facilities 110. As may be appreciated, data provided by the healthcare facilities 110 may be in a proprietary data format that may or may not be readable by third parties without use of corresponding proprietary software executed by the healthcare facility 110.


In an embodiment, the backup data portion 130 may be operative to provide a backup version of data to any one or more of the healthcare facilities 110. For instance, in the event of a data loss at any one or more of the healthcare facilities 110a-110c, the backup data portion 130 may be able to provide a backup copy of a database to the healthcare facility 110 for the purposes of restoring the database. That is, data provided from any respecting one of the healthcare facilities 110 may be provided back to the given healthcare facility 110 as a data backup. As such, provision of the medical information by the healthcare facilities 110 may provide the facilities 110 benefit in the form of a data backup. Thus, medical information that relates to patient health may be efficiently backed up at the backup data portion 130 and available for restoration at the healthcare facility 110 in the event of a data loss at the facility 110.


The data storage device 120 may also include a shareable data portion 150. The shareable data portion 150 may store data records that have at least a portion of the medical information redacted therefrom. For example, in an embodiment, records in the shareable data portion 150 may have personal health information (PHI) removed therefrom. In this regard, a data screening module 140 may be provided. The data screening module 140 may access the complete data records stored in the backup data portion 130. The data screening module 140 may remove one or more portions of data (e.g., PHI or other patient identifying information) from the records. In turn, the redacted data records may be stored in the shareable data portion 150.


As such, the backup data portion 130 and the shareable data portion 150 may be separated such that access to each respective data portion may be controlled. While the data portions may reside on the same device (e.g., a common drive, server, or the like), the data portions may be segregated such that access on one portion may not allow for access to the other. In an embodiment, the data portions may be stored on different corresponding devices.


It may be advantageous to provide associations between the data records correspond to a given patient even if the given patient is not identified (i.e., even if the records are redacted). Thus, the system 100 may be operative to associate redacted records and a patient to determine what medication preparations were associated with a given patient without providing information that identifies the actual patient. As the identity of the patient may comprise PHI, the identity of the patient may be redacted from the record while still providing an associative relationship between all records for a given patient. That is, the data screening module 140 may generate a unique identifier that corresponds to a given patient but is not capable of identifying the patient. As such, all data records associated with that patient may be assigned the unique identifier corresponding to the patient. All data records for the given patient may therefore be identified while the identity of the patient themselves may not be provided.


One example of a unique identifier may comprise a hash value generated by application of a cryptographic hash function to one or more portions of the complete data record prior to storing the redacted record in the shareable portion 150. In turn, the redacted data records may be stored with a generated hash value, which may comprise a unique identifier. In an embodiment, the complete dose record may include one or more patient identifier. For instance, the dose records may include field containing the patient name and/or other identifying information related to the patient such as, for example, a facility identifier for the patient, a date of birth, a social security number, or other patient identifying information as described above. Accordingly, the patient identifier may include PHI. In turn, any one or more of the patient identifiers of the complete dose record may comprise an input to the hash function. The resulting hash value output may provide the unique identifier that may be stored in corresponding relation to the redacted data records stored in the shareable data portion 150.


The data screening module 140 may apply a hash function to one or more patient identifier fields of the complete dose order records. For instance, one or more cryptographic hash functions may be applied such as, for example, SHA-1, SHA-2, SHA-3, MD5, RIPEMD-128/256, RIPEMD-320, RTR0, or other appropriate hash functions now existing or later developed. Preferably, the applied hash function is deterministic. That is, for each given unique input a corresponding unique output is provided by the function without data collisions. Furthermore, the hash function is preferably non-invertable. For example, when provided with a hash value resulting from the hash function, the input that resulted in the hash value should not be ascertainable. Thus, the hash function preferably provides a one-way conversion of the patient identifier to a non-identifying unique value that is unique for each given one of a plurality of patients. In turn, the unique value for a given patient may be the same each time the hash function is applied. Thus, two or more different dose order records associated with a given patient may both receive the same unique identifier upon application of the hash function to the records. As such, a review of the resulting redacted dose order records containing the unique identifier in place of a patient identifier may allow for dose order records corresponding to a given patient may be identified based on a common unique value (e.g., a hash value). The hash value may also be further encoded, e.g. using Base64 encoding on the resulting hash value.


The system 100 may also include a collaboration module 160. The collaboration module 160 may access the shareable data portion 150 containing the redacted data records. In turn, the collaboration module 160 may retrieve the redacted data records for transformation into a format that may be useable by one or more remote users 170 and/or local users 165 of the system 100. The format into which the collaboration module 160 transforms the redacted data may be at least partially based on a predetermined operational need of the local user 165 or remote user 170 that requests the data from the collaboration module 160.


The collaboration module 160 may facilitate selective, secure access to local users 165 and/or remote users 170 who wish to access the formatted data extracted by the collaboration module 160 from the shareable data portion 150. In this regard, a plurality of access layers may be provided that must be satisfied by users prior to accessing the formatted data from the shareable data portion 150. For instance, the remote user 170 may be required to access a first layer such as a virtualized private network (VPN) or the like. Accessing the VPN may require a remote user 170 to provide appropriate credentials (e.g., a valid user name and password combination, a cryptographic key, a one-time password, a biometric value, etc.). A local user 165 may be required to be utilizing an access terminal on a common network with the collaboration module 160 (e.g., a local area network or the like). A user may then access the collaboration module 160 with further credentials (e.g., a valid user name and password, a cryptographic key, a one-time password, a biometric value, etc.). Once the user has joined the VPN or accessed the collaboration module 160 on a common network and provided the necessary credentials to access the collaboration module 160, the user may have access to the formatted data at the collaboration module 160 based on the redacted data records in the shareable data portion 150. As such, a plurality of access layers may be provided to reduce unauthorized access to the shareable data portion 150.


The collaboration module 160 may access the redacted data records in the shareable data portion 150 and extract the data therefrom. In turn, the collaboration module 160 may transform the data into a given format that is loaded (e.g., to a storage device at the collaboration module 160 and/or in the shareable data portion 150) for access by users 165/170. The format of the data may comprise a standardized format. The standardized format may in turn be accessible by all those who access the collaboration module 160. The standardized format may include an extensible markup language (XML) format. The standardized format may additionally or alternatively be provided as a delineated text file, a pivot table, or any other standardized format or data view. In this regard, data that may be provided in a proprietary format (e.g., as described above) may in turn be formatted such that the data may be accessed and/or viewed by other parties/users that are incapable of viewing the data in the proprietary format provided. As such, the data may be more widely disseminated to provide further data analytics relative thereto.


In an embodiment, the collaboration module 160 may format the redacted data from the shareable data portion 150 into a format at least in part based on the user who is to access the data, an application in which the data is to be used, a requested format of the user, and/or other appropriate criteria. For instance, different remote users 170 may have access to the collaboration module. As described above, access to the collaboration module 160 by a remote user 170 may include one or more layers of access protocols that require authentication including, for example, providing a user name and password. In this regard, access to the collaboration module 160 may at least in part identify the remote user 170 accessing the collaboration module 160. In this regard, the format of the data to which a remote user 170 has access may at least depend on the identity of the user 170. For instance, a first remote user 170 may be associated with a first party and receive the formatted data in a first format associated with the first party (e.g., a proprietary data format corresponding to the first party). A second remote user may be associated with a second party and receive the formatted data in a second format associated with the second party (e.g. a proprietary format associated with the second party). The first and second formats may be different and may be unique to the particular user accessing the collaboration module 160. As will be described in greater detail below, different remote users 170 of the formatted data provided by the collaboration module 160 may have different operational needs as it relates to the data stored in the shareable data portion 150. As such, the format of the data presented to a user 165/170 may be based on an anticipated use of the data and/or a requested format by the user 165/170.


As may be appreciated in FIG. 1, the data storage module 120 and collaboration module 160 may collectively comprise a collaboration system 305. In this regard, the healthcare facilities 110a-110c may comprise data sources that provide data to the collaboration system 305. In turn, users 170 and/or 165 may access the data provided by the data sources 110a-110c by utilizing the collaboration system 305. In this regard, the embodiment depicted in FIG. 1 provides one exemplary embodiment of a collaboration system 305, however as will be appreciated in further reference to FIG. 2 below, other embodiments of collaboration systems 305 are contemplated.


Furthermore, the various components depicted in FIG. 1 may be in operative communication over one or more networks. That is, the various modules and devices depicted may each be in operative, networked communication. The network communications may utilize a wide area network such as the Internet or the like. Additionally or alternatively, the communications may be by way of one or more local area networks, intranets, private networks, or the like. Furthermore, the modules and devices may comprise integrated systems or may be provided discretely. For instance, in an embodiment, the data storage device 120 may include discrete hardware for each of the backup data portion 130 and the shareable data portion 150. For instance, each respective data portion may be provided on separate hardware such as separate hard drives, separate servers, or the like. Alternatively the portions may comprise segregated data spaces on a common device such as a common hard drive, a common server, or the like. In this same regard, the data screening module 140 and/or collaboration module 160 may each be stand alone modules executing on discrete hardware devices or either module may be executed on a common hardware device that may or may not also contain the backup data portion 130 and/or the shareable data portion 150.



FIG. 2 depicts another embodiment of a system 200 for exchange of information. The variations and details described above in relation to FIG. 1 may be applicable to the system 200 of FIG. 2 unless specified otherwise. The system 200 generally includes healthcare facilities 210a and 210b that are in operative communication with a primary data storage device 222. The primary storage device 222 may be in operative communication with a secondary or backup data storage device 224. In turn, a datamart module 260 may be in operative communication with the backup data storage device 224. Remote users 270 may access the datamart module 260. In turn, medical information received from the healthcare facilities 210a and 210b may be selectively provided to the remote users 270 for advantageous data analytics relative thereto.


As shown in FIG. 2, each healthcare facility 210 may include a backup services module 212. The backup services module 212 may be in operative communication with one or more local database of the healthcare facility. For instance, the backup service module 212 at the healthcare facility 210a may be in operative communication with local databases 214 and 216. In this regard, local databases 214 and 216 may store information at the healthcare facility 210a. Backup service 212 at healthcare facility 210b may be in operative communication with a local database 218 at healthcare facility 210b. In an embodiment and as described above, the information may include dose order records corresponding to dose orders for medication preparations to be administered to a patient.


In any regard, the backup service module 212 may access a local database at the healthcare provider 210 and provide information to the primary data storage device 222. The backup service module 212 may periodically poll the one or more databases with which it is in operative communication and provide any new or modified records to the primary data storage device 222. Alternatively, the backup service module 212 may continuously monitor one or more database and provide records to the primary data storage 232 in a real time or near real time basis.


The backup service module 212 may also apply a local backup policy established by each respective healthcare facility 210. For instance, a healthcare facility 210 may wish not to provide information containing certain data fields (e.g., those fields corresponding to patient identifiers and/or PHI) to the primary data storage device 232. In this case, the backup service 212 may facilitate redaction of one or more portions of the data from the data prior to providing the data to the primary data storage device 232. In an embodiment, the backup service module 212 may be operative to generate a unique identifier corresponding with a given patient as was discussed above in connection with the data screening module 140. That is, the backup service module 212 may locally generate a unique value that uniquely associates a given patient with one or more data records, yet is non-identifying of the patient. As such, the backup service 212 may be operative to apply a hash function to the data records to redact a patient identifier from the records. In turn, the information provided from the backup service 212 to the primary data storage device 222 may include a unique identifier in lieu of patient identifying information.


The primary data storage device 222 may include a backup data portion 232 at the primary data storage device 222. The primary data storage device 222 may also be in operative communication with a backup data storage device 224. The backup data storage device 224 may include a backup data portion 234. The backup data portion 232 of the primary data storage device 222 may be replicated and stored in the backup data portion 234 of the backup data storage device 224. The primary data storage device 222 and the backup data storage device 224 may be distributed at distinct geographic locations. For example, the primary data storage device 222 may be located at a first geographic location on the east coast of the United States and the backup data portion 224 may be located at a second geographic location on the west coast of the United States. Periodically, the primary data storage device 222 may communicate data from the backup data portion 232 to the backup data portion 234 of the backup data storage device 224. As such, a backup of the backup data portion 234 may be stored at each location. Accordingly, the use of geographically distributed storage device locations may reduce the potential for data loss at both facilities simultaneously. Thus, in addition to the primary data storage device 222 facilitating data backup services for the healthcare facilities 210, a further backup potential is created by use of the backup data storage device 224. As such, in the event of a data loss at a healthcare facility 210 and/or the primary data storage device 222, the backup data storage device 224 may provide backup copies of data to the facility 210 and/or primary data storage device 222 to facilitate data recovery.


The backup data storage device 224 may include a data screening module 240. Although, the data screening module 240 could be located at the primary data storage device 224 in addition to or as an alternative to the backup data storage device 224 without limitation. In either regard, the operation of the data screening module 240 would be the same. As described in relation to FIG. 1, the data screening module 240 may generate a unique identifier associated with a patient identifier for the purpose of redacting a portion of the data records (e.g. including patient identifiers and/or PHI) to be stored in a shareable data portion 250 at the backup data storage device 224. In the embodiment depicted in FIG. 2, data records may be provided in a redacted form from the backup service module 212 at the healthcare facility. In this regard, the data screening module 240 may further redact the data records or pass the previously redacted records on to the shareable data portion 250. In any regard, the information stored in the shareable data portion 250 may be redacted (e.g., the data may have patient identifiers and/or PHI removed therefrom).


The shareable data portion 250 may be in operative communication with a collaboration module 262. The collaboration module 262 may be provided in a datamart module 260. The datamart module may allow for the collaboration module 262 to extract, transform (e.g., format), and load formatted data into a datamart storage device 264 for access by remote users 270. Again, the formatted data may be provided in a standardized form or may be provided in particular given forms accessible by the remote users 270 as discussed above.


In this regard, FIG. 2 depicts another embodiment of a collaboration system 305 the comprises the primary data storage device 222, the backup data storage device 224 and the data more module 260. In this regard, collaboration system 305 may include geographically remote backup data storage devices for the purpose of providing additional data redundancy. In this regard, the healthcare facilities 210a and 210b may comprise data sources that provide medical information to the collaboration system 305. In turn, the collaboration system 305 may provide access to the redacted and formatted medical information to remote users 270.



FIG. 3 depicts a schematic view of an embodiment of a collaboration platform 300 that may be used to provide medical information from one or more data sources to users for the purpose of facilitating data analytics on the medical information. The collaboration platform 300 may include a collaboration system 305. The collaboration system 305 may comprise a system such as collaboration system 305 described above in relation to system 100 shown in FIG. 1 or collaboration system 305 shown in FIG. 2. In any regard, the collaboration system 305 may receive information from a healthcare facility 310. In turn, the information may be provided in a shareable data portion of the collaboration system 305 for access by users such that the information received from the healthcare facilities 310 is transformed prior to access by one or more third parties. For instance, the transformation may include redacting patient identifiers and/or PHI from the data and/or transforming the data into a format useful to users of the system 305.


However, the collaboration system 305 may also be in operative communication with one or more other sources of data in addition or as an alternative to the healthcare facilities 310. For instance, the collaboration system 300 may be in operative communication with a medical device operational database (e.g., a dose administration device database or other appropriate source of medical device information), a hospital information system 314, external pharmacy resources 316, and/or any other appropriate source of medical information. In the event the medical information received from the data source (e.g., the healthcare facility 310, the medical device operational database, the hospital information system 314, the external pharmacy resources 316 and/or any other appropriate source of medical information) contains information to be redacted (e.g., patient identifiers and/or PHI), the collaboration system 305 may be operative to redact the medication information and, for instance, generate a unique identifier that is related to, but does not identify a patient as described above.


The collaboration system 305 may provide access to formatted data generated from one or more data sources. The data provided by the collaboration system 305 may include redacted data records with patient identifiers and/or PHI removed therefrom regardless of the source of the data. The data provided by the collaboration system 305 may also be formatted as described above in relation to the embodiments of collaboration modules discussed above. The collaboration system 305 may thus format data from a plurality of sources that may originate in different formats. As such, the collaboration system 305 may be operative to combine and/or aggregate data from the different sources for presentation to users in a standard or particular format.


The collaboration system 305 may, thus, aggregate and format a large amount of medical data from a plurality of sources. In turn, users may access the aggregated and formatted data of the collaboration system 305. Such users may be local users 320 that locally access the collaboration system 305 (e.g., are users on a common network with the collaboration system 305 such as users of a local area network, intranet, or the like). Thus, internal analytics within a given organization may be facilitated. Furthermore, external users 330 may access the collaboration system 305 (e.g., users that access the system 305 by way of a wide area network or the like). In turn, internal analytic users 320 and/or external service providers 330 may have access to the collaboration system 305. The format available to and/or accessible by different users may depend upon the user's identity, whether the user is an internal or external user, and/or a given purpose for which the user is accessing the data.


The modules described herein may comprise software, hardware, or a combination of both. For instance, the modules of the system may include specifically configured hardware such as application specific integrated circuits (ASICs), programmable field gate arrays, or other appropriate processors. In an embodiment, the modules may include a microprocessor in operative communication with a memory. The memory may comprise a non-transitory computer readable medium that may include machine-readable instructions. As such, the processor may access the memory and be specifically configured by the machine-readable instructions stored therein to execute any of the functionality described herein. Additionally, the modules described above may be executed using a common processor in operative communication with a memory that provides the functionality of a plurality of modules. In this regard, the modules may be executed using a single common processor or different modules may be executed using different processors.


Turning to FIG. 4, an embodiment of a method 400 for exchange of medical information by way of a collaboration platform is depicted in the form of flow chart. The method may include collecting 402 information from one or more data sources. As described above, the data sources from which medical information is collected may include healthcare facilities, medical device operational databases, hospital information systems, external pharmacy resources, or any other appropriate sources of medical information. In turn, the method 400 may include storing 404 medical information in a backup data portion. As described above, the shareable data portion may comprise a portion of a data storage device.


In an embodiment, the method 400 may include creating 406 backup data records. The back of data records may comprise a copy of complete records stored in the backup data portion. The backup data records may be stored in a remote geographic location separate from the backup data portion stored in step 404. In turn, the backup data records may be used to restore lost or corrupted data at a healthcare facility and/or other data source.


The method 400 may also include accessing 408 the complete medical information (e.g., the complete data records). As described above, it may be beneficial to redact a portion of the complete data records to, for example, remove patient identifying information therefrom. In this regard, the method 400 may include redacting 410 one or more portions of information from the medical records accessed at step 408. As described above, the redacting 410 may include applying a hash function to generate hash value based at least in part on a portion of the data records including, for example, a patient identifier and/or PHI. The method 400, in turn, includes storing 412 the redacted medical information in a shareable data portion. The shareable data portion may be separate from the backup data portion such that selective access to either portion may be separately facilitated.


In an embodiment, the method 400 includes extracting 414 the redacted records from the shareable data portion. The method 400 may further include formatting 416 redact data records into a data format that may be useful to a user accessing the redacted records (e.g., for purposes of data analytics). In this regard, the format may be standardized format presented all users of the system or may be particularly directed to a particular user and/or data analytic context for which the data is to be used. The method 400 may further include loading 418 the formatted redacted records (e.g., by a collaboration module or the like) to facilitate access to the formatted redacted records. In turn, the method 400 may include permitting 420 selective, secure access to the formatted redacted data records by users of the platform. As described above, the users may each have access to a standardized format or may be presented with a specific format of data based on the identity user, and indicated application for which the data is to be used, or a requested format type by the user.


In turn, the medical information collected 402 from the various sources of medical information may be transformed and made available to users to perform, for example, data analytics on the medical information. Accordingly, the method 400 may include performing 422 data analytics with respect to the formatted redacted records there selectively accessed 420. Examples data analytics may include, for example, monitoring trends with respect to ordered doses for the purpose of improving patient safety relative to the ordered doses and/or improving business opportunities by gaining actionable business intelligence data relative to the activities corresponding to the medical information gained from the one or more sources. Other data analytics may be contemplated such as those described in greater detail below. In this regard, the data analytics may be provided in the form of the plurality of services by users may access and/or perform data analytics on the redacted, formatted medical information in a cloud architecture (e.g., using networked resources) to facilitate improved efficiency, speed, and/or utilization of resources relative thereto.



FIG. 5 depicts an embodiment of a platform 500 utilizes a collaboration system 305 aggregate data in turn provide redacted formatted data to one or more users who in turn access the data. As such, the collaboration system 305 may comprise a collaboration system according to the embodiment of a collaboration system 305 depicted in FIG. 1 and/or embodiment of a collaboration system 305 depicted in FIG. 2. Furthermore, any other appropriate combination of modules, components, or other devices comprising a collaboration system 305 and provided that facilitates redaction and formatting of medical information provided from one or more sources. In this regard, collaboration system 305 may include additional or fewer modules than those described with respect to the specific embodiments described in FIGS. 1 and 2. As such, the embodiments depicted in FIG. 1 and FIG. 2 are exemplary, but not limiting.


In FIG. 5, the collaboration system 305 is discussed in relation to the context of preparation of a dose for a patient. In this regard, the solid arrow lines in FIG. 5 may represent flow of physical goods between the various entities described. The dash-dot lines in FIG. 5 represent flow data between the various entities in the collaboration system 305. Accordingly, the platform 500 shown in FIG. 5 represents one particular application of a collaboration system 305 is a relates to the flow of materials in connection with preparation and administration of the dose to the patient and healthcare facility.


The platform 500 may include a pharmaceutical manufacturer 510. The pharmaceutical manufacturer 510 may manufacture a medical product of a dose such as a drug compound and/or other intermediaries including diluents or the like. Accordingly, the pharmaceutical manufacturer 510 may provide the manufactured medical product to a hospital that employs a hospital information system 512. Specifically, an inventory management system at a healthcare facility may be executed by the hospital information system 512 may allow for receipt and tracking of goods from the pharmaceutical manufacturer 510.


The pharmaceutical manufacturer 510 may also provide data to the collaboration system 305. In this regard, the pharmaceutical manufacturer 510 may comprise a data source that provides medical information collaboration system 305. Examples of pertinent data that the pharmaceutical manufacturer 510 may provided the collaboration system 305 may include for example, medical product identifiers, lot numbers, expiration dates, inventory management numbers, product concentrations, product sizes, or other information related to medical products manufactured by the pharmaceutical manufacturer 510.


The inventory management component of the hospital information system 512 may, after receipt of medical products from the pharmaceutical manufacturer 510, monitor the medical products including, for example at time in which a medical product is requested at a pharmacy and/or track information associated with medical products including, for example lot numbers, expiration dates, product identifiers, or the like. As such, a pharmacy workflow manager 514 may be provided in the pharmacy of a healthcare facility. The pharmacy workflow manager 514 may receive products from the inventory management system of the hospital information system 512. For instance, the pharmacy workflow manager 514 may request medical products for use in preparation of doses from the inventory management system 512. As such, inventory management system 512 may facilitate provision of medical products to the pharmacy for tracking by the pharmacy workflow manager 514.


The inventory management portion of the hospital information system 512 may also provide data to the collaboration system 305. Exemplary data may include, for example, average inventory levels, current inventory levels, inventory supply parameters including average durations a medical product is maintained in stock prior utilization, and/or data concerning the movement of medical products within a hospital including, for example, provision of drug products to the pharmacy workflow manager 514 for use in preparation of a dose.


The pharmacy workflow manager 514 may facilitate preparation of doses for administration to patients. As described above, the preparation of doses may be in response to received dose orders from healthcare providers or the like. As such, the pharmacy workflow manager 514 may receive dose order information as described above. Furthermore, the pharmacy workflow manager 514 may supplement such data with information related to the preparation of the dose. For example, images may be captured related to the medical product(s) utilized to prepare the dose. Furthermore, data may be gathered from medical products and used to populate specific dose order records corresponding to a dose order. The dose order may or may not be patient specific. In this regard, the dose order record may include information regarding a lot number or an expiration date of a medical product used to prepare the dose. Additionally, the pharmacy workflow manager 514 may supplement data such as the identity of the pharmacy technician who prepared the dose, the pharmacist who approved the dose, as well as parameters related thereto such as the time/date when such events occurred. Furthermore, the pharmacy workflow manager 514 may present to a pharmacy technician a protocol for use in preparation of the dose. The specific protocol utilized may also be associated with the dose order record.


The pharmacy workflow manager 514 may also provide data to the collaboration system 305. In this regard, the one or more portions of the data described above that is the generated and/or received by the pharmacy workflow manager 514 may be provided. In this regard, the pharmacy workflow manager 514 may provide information related to the preparation of a dose and/or related to the medical product(s) used to prepare the dose. Furthermore, the data provided by the pharmacy workflow manager 514 to the collaboration system 305 may include information related to the time/date at which certain events relative to the dose order occur. The pharmacy workflow manager 514 may also detect errors that occur during the preparation of the dose order. For example, a pharmacy technician may scan an incorrect medical product to be used in connection with the dose to be prepared. While the pharmacy workflow manager 514 may alert the pharmacy technician of the error such that it may rectified, the pharmacy workflow manager 514 may further record the performance of the error in connection with the dose order with which it occurred.


The pharmacy workflow manager 514, upon dispensation of a dose from the pharmacy, may provide the dose to a dose dispensing cabinet 516. The dose dispensing cabinet 516 may be accessible by patients, healthcare facility personnel, or others to retrieve a dose once prepared. This regard, the dose dispensing cabinet 516 may track and/or collect certain information related to the dose. Examples of such data may include the time a dose is placed or retrieved in the dispensing cabinet 516 prior to retrieval, the identity of a person stocking and/or retrieving a dose from the dose dispensing cabinet 516, number of available doses in the dispensing cabinet 516, the number of free storage areas in the dose dispensing cabinet 516, or other relevant data. The dose dispensing 516 may also track errors related to the retrieval of dose orders from the dose dispensing 516. For example, unauthorized attempts to access storage location may be recorded. Furthermore, erroneous attempts to access storage location or attempt to access the incorrect story location may also be tracked. As such, any or all the data collected or available to the dose dispensing cabinet 516 may also be provided to the collaboration system 305.


Once the dose is retrieved from the dose dispensing cabinet 516, the dose may be administered to a patient using an administration device 518. That is, healthcare facility personnel such as a nurse or the like may retrieve a dose from the dose dispensing cabinet 516. The dose may in turn be connected to an administration device 518. The administration device 518 may, for example, be an infusion pump utilized to deliver the dose to a patient. In this regard, the administration device 518 may record information regarding the dose administered such as, the patient to which the doses administered, or other relevant information such as the time of administration, parameters regarding the administration (e.g., administration rate, administration duration, etc.), or other information collected regarding the administration of the dose. The administration device 518 may further provide any such information it has access to or generates to the collaboration system 305.


Once doses are delivered to a patient, a patient record portion of a hospital information system 520 may be updated to record the administration of the dose to the patient. For example, parameters such as the hospital personnel responsible for the administration of the dose, the time/date of the dose, or other relevant medical record information including health care provider notes or the like be recorded in the patient records of the hospital information system 520. Furthermore, this information may also be provided to the collaboration system 305. The administration device 518 may further track errors. For example, the administration device 518 may include checks to ensure proper programming of the administration device 518. In the event that an improper programming is made, the error may be recorded by administration device 518.


Accordingly, the collaboration system 305 may collect information from the various stages related to the manufacture, preparation, and/or administration of the dose to the patient. As described above, the collaboration system 305 may aggregate, redact, and format such data. In turn, the collaboration module of the collaboration system 305 may allow access to the aggregated, redacted, and formatted data for purposes of data analytics. As briefly stated above, it may be valuable for the sources of data (e.g. any one or more of the entities described in FIG. 5) to not only provide data to collaboration system 305, but also retrieve data from the collaboration system 305 for a number of different reasons. As may be appreciated in FIG. 5, the entities shown may not only provided to collaboration system 305 may also each comprise users that in turn have access to the collaboration system 305 to access the aggregated, redacted, and formatted data. In this regard, by virtue the collaboration system 305 providing redaction and formatting, any one or more of the entities shown in FIG. 5 may have access to a shareable data portion of the collaboration system 305 to gain access to data for use in data analytics.


This may open the available data to each one of the specific entities beyond that for which they are solely responsible. That is, the pharmaceutical manufacturer 510 may access the collaboration system 305 to obtain data related to the hospital information system 512 and/or 520, a pharmacy workflow manager 514, a dose dispensing cabinet 516, or an administration device 518. Absent the collaboration system 305, the collection in or use of such data may be arduous at each individual one of the entity shown in FIG. 5 may be required to solicit information directly from other entities and be subjected to concern such as data privacy and security. However, the collaboration system 305 may provide a central aggregation, redaction, and formatting of a pool of shared data that in turn provides efficient access to data for purposes the data analytics beyond that available for each individual entities on portion of the data supplied to collaboration system 305.


Some relevant examples of data analytics that made performed utilizing the platform 500 shown in FIG. 5 may include analysis that provides for improved patient safety, medical results, inventory management, business insight, security, or other useful outcomes related to the data analysis. For example and as described above, errors may be tracked at one or more the pharmacy workflow manager 514, dose dispensing cabinet 516, or administration device 518. In an effort to improve patient safety, a pharmaceutical manufacturer 510 may review data provided by the collaboration system 305. As the data aggregated by the collaboration system 305 may provide insights to the occurrence of errors with respect to a number of parameters including a particular medical product utilized to prepare the dose, the pharmaceutical manufacturer 510 may determine if error rates at any one or more of the pharmacy workflow manager 514, dose dispensing 516, or administration device 518 are more prevalent with a particular medical product. Identification of such trends may in turn allow the pharmaceutical manufacturer 510 to determine a root cause of a source of the error and remedy the root cause. For example, in the pharmacy workflow manager 514, confusing labeling of packaging may result in an increased error rate with respect to a particular medical product. In turn, the pharmaceutical manufacturer 510 may identify the increased error rate with respect to the medical product and in turn launch a root cause analysis. In turn, a source of the error in the form of the confusing labeling may allow the pharmaceutical manufacturer 510 to improve the labeling and reduce the errors associated with the medical product.


Similarly, one or more of the entities in FIG. 5 may be interested in analytics with respect to inventory for purposes of improving supply-chain characteristics at any one or more portions of the supply chain between the pharmaceutical manufacturer and the administration of the dose to the patient. For example, the data provided by the collaboration system 305 allow for analytics with respect to turnaround times, throughput of doses, cycle times, or the like. Furthermore, information provided the various sources of data may allow for analysis with respect to the best source doses. For example, a pharmacy workflow manager 514 may determine, based on data analyzed from the collaboration system 305, whether it is more efficient to produce a dose within the pharmacy or, for example, buy premade doses from an outside vendor. Furthermore, an entity responsible for a dose dispensing cabinet 516 may utilize data retrieved the collaboration system 305 determine whether diversion a product from the dose dispensing cabinet is occurring.


In this regard, number of valuable parameters contained within the data provided by the collaboration system 305 may be leveraged to provide useful insights during data analytics. Specifically, given the foregoing discussion regarding the de-identifying of medical information while preserving the ability to associate various portions of the medical information with a given patient, patient specific analysis may be undertaken. This may be useful for providing insight regarding administration of doses to particular patient. For example, the delay between dose order entry and dose administration may be examined with respect particular patients. In turn, correlations with respect to types of medication, administration routes of medication, the nursing unit associated with the doses, or even facilities in general, can be made. That is, metrics with regard to these various parameters may be examined in connection with delays between dose order and administration to provide increases in efficiency for the process of preparing and administering the doses to a patient. Such may be particularly valuable in urgent or “STAT” doses with the understanding that the time sensitivities associated with such doses may be critical to patient outcomes in certain instances such as an emergency context.


While the invention has been illustrated and described in detail in the drawings and foregoing description, such illustration and description is to be considered as exemplary and not restrictive in character. For example, certain embodiments described hereinabove may be combinable with other described embodiments and/or arranged in other ways (e.g., process elements may be performed in other sequences). Accordingly, it should be understood that only the preferred embodiment and variants thereof have been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected.

Claims
  • 1. A system for an exchange of information related to dose preparation, the system comprising: a data storage device in operative communication with a plurality of healthcare facilities, wherein the data storage device is configured to receive, from the plurality of healthcare facilities, information regarding a plurality of dose preparations prepared at the plurality of healthcare facilities, including receiving first information from a first healthcare facility regarding a first dose preparation prepared at the first healthcare facility for administration to a first patient and receiving second information from a second healthcare facility regarding a second dose preparation prepared at the second healthcare facility for administration to a second patient, wherein the data storage device comprises (i) a sharable data portion that stores redacted data records for each of the plurality of dose preparations having patient identifying information removed therefrom and (ii) a backup data portion that stores data records for each of the plurality of dose preparations including the patient identifying information, the sharable data portion configured to have a first access control and the backup data portion configured to have a different, second access control to prevent cross-access between the sharable data portion and the backup data portion;a processor that is in operative communication with the data storage device, the processor configured to perform a cryptographic operation on the patient identifying information to create unique hash values,create redacted data records storing the unique hash values instead of the patient identifying information, where a first unique hash value is used for the redacted data records that are related to the first patient and a second unique hash value is used for the redacted data records that are related to the second patient, andstore the redacted data records that are related to the first patient and the redacted data records that are related to the second patient to the sharable data portion; anda collaboration module that is in operative communication with the data storage device, wherein the collaboration module is configured to access the shareable data portion using the first access control,extract data from the shareable data portion,transform the extracted data into a data format based at least in part on a predetermined operational need specified by a third healthcare facility or a third-party, andload the formatted data into a remotely accessible data storage location that is accessible remotely from the data storage device,wherein the third healthcare facility or the third-party remotely accesses the formatted data from the remotely accessible data storage location, such that the third healthcare facility or the third-party uses the formatted data at the third healthcare facility.
  • 2. The system of claim 1, wherein the patient identifying information comprises protected health information (PHI) that at least comprises a patient identifier.
  • 3. The system of claim 2, wherein the first unique hash value includes a unique identifier that associates one or more portions of the information regarding the first patient without providing identifying characteristics relative to the first patient.
  • 4. The system of claim 3, wherein the unique identifier comprises the first unique hash value that is generated in response to the application of the cryptographic operation to the patient identifier.
  • 5. The system of claim 4, wherein the processor is part of the data storage device for generating the redacted data records that are stored in the shareable data portion.
  • 6. The system of claim 4, wherein the processor is located at the plurality of healthcare facilities for generating the redacted data records that are received at the data storage device for storage in the sharable data portion.
  • 7. The system of claim 1, wherein each of the unique hash values comprises a deterministic, non-invertable value based on the patient identifier.
  • 8. The system of claim 1, wherein the backup data portion comprises complete data records including the patient identifying information corresponding to at least a portion of the information regarding the plurality of dose preparations received from the plurality of healthcare facilities.
  • 9. The system of claim 8, wherein the backup data portion and the shareable data portion are separately accessible on the data storage device.
  • 10. The system of claim 1, wherein the collaboration module provides a plurality of users selective and secure access to the shareable data portion based on a plurality of security layers applied to access the shareable data portion.
  • 11. The system of claim 10, wherein the data format comprises a standardized data format accessible by the plurality of users.
  • 12. The system of claim 10, wherein the data format comprises a plurality of distinct data formats, wherein different ones of the plurality of distinct data formats are accessible by corresponding different respective ones of the plurality of users.
  • 13. The system of claim 1, wherein the data storage device comprises a data storage server located remotely from the plurality of healthcare facilities.
  • 14. The system of claim 13, wherein the data storage device comprises a plurality of mirrored data servers distributed at distinct geographic locations.
  • 15. The system of claim 1, wherein the information regarding the plurality of dose preparations comprises dose order records generated in response to received dose orders for the plurality of dose preparations to be administered.
  • 16. The system of claim 1, further comprising: an analytics module in operative communication with the remotely accessible data storage location to retrieve the formatted data,wherein the analytics module is operative to perform at least one analysis on the information regarding the first dose preparation for administration to the first patient without the particular identity of the first patient.
  • 17. The system of claim 16, wherein the at least one analysis comprises at least one of error analysis, inventory management, or supply chain management.
  • 18. The system of claim 1, wherein the information regarding the plurality of dose preparations is received at the data storage device in accordance with a local data policy of each respective one of the plurality of healthcare facilities.
  • 19. A method for generating shareable information regarding dose preparation, the method comprising: receiving, from a plurality of healthcare facilities, information regarding a plurality of dose preparations prepared at the plurality of healthcare facilities, including receiving first information from a first healthcare facility regarding a first dose preparation prepared at the first healthcare facility for administration to a first patient and receiving second information from a second healthcare facility regarding a second dose preparation prepared at the second healthcare facility for administration to a second patient;storing the information as a backup data portion stored on a data storage device in the form of data records for each of the plurality of dose preparations including patient identifying information;storing the information as a shareable data portion stored on the data storage device in the form of redacted data records for each of the plurality of dose preparations having the patient identifying information removed therefrom;configuring a first access control for the sharable data portion and configuring a different, second access control for the backup data portion to prevent cross-access between the sharable data portion and the backup data portion;performing, via a processor, a cryptographic operation on the patient identifying information to create unique hash values;storing, via the processor to the data storage device, a unique hash value to each of the redacted data records instead of the patient identifying information, where a first unique hash value is used for the redacted data records that are related to the first patient and a second unique hash value is used for the redacted data records that are related to the second patient;formatting, via the processor, the redacted data records to a format corresponding with a predetermined operational need of a third-party; andloading, via the processor, the formatted data into a remotely accessible storage location for access by users remote from the remotely accessible storage location that are associated with the third-party.
  • 20. The method of claim 19, wherein the patient identifying information comprises protected health information (PHI) that comprises at least a patient identifier.
  • 21. The method of claim 20, wherein the first unique hash value includes a unique identifier that corresponds to the first patient and does not provide identifying capability relative to the first patient.
  • 22. The method of claim 21, wherein the storing further comprises: generating the unique identifier in response to applying the cryptographic operation to the patient identifier.
  • 23. The method of claim 19, further comprising: providing a plurality of users selective and secure access to the redacted data records.
  • 24. The method of claim 23, wherein the formatting comprises formatting the redacted data records to a standardized format accessible by the plurality of users.
  • 25. The method of claim 23, wherein the formatting comprises formatting the redacted data records to a plurality of distinct data formats, wherein different ones of the plurality of distinct data formats are accessible by corresponding different respective ones of the plurality of users.
  • 26. The method of claim 19, further comprising: generating the information regarding the plurality of dose preparations comprising dose order records in response to received dose orders for the plurality of dose preparations to be administered.
  • 27. The method of claim 19, further comprising: accessing the remotely accessible storage location to retrieve the formatted data; andanalyzing the information regarding the first dose preparation for administration to the first patient without the particular identity of the first patient.
  • 28. The method of claim 27, wherein the analyzing comprises at least one of error analysis, inventory management, or supply chain management.
  • 29. The method of claim 19, wherein receiving the information regarding the plurality of dose preparations is at least partially based on a local data policy of each respective one of the plurality of healthcare facilities.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority from U.S. Provisional Application No. 62/019,227, filed on Jun. 30, 2014, entitled “MANAGED MEDICAL INFORMATION EXCHANGE,” the contents of which are incorporated by reference herein as if set forth in full.

US Referenced Citations (1029)
Number Name Date Kind
641748 Smith Jan 1900 A
819339 Cleland May 1906 A
3426150 Tygart Feb 1969 A
3739943 Williamsen et al. Jun 1973 A
3742938 Stern Jul 1973 A
3756752 Stenner Sep 1973 A
3774762 Lichtenstein Nov 1973 A
3786190 Pori Jan 1974 A
3809871 Howard et al. May 1974 A
3810102 Parks et al. May 1974 A
3848112 Weichselbaum et al. Nov 1974 A
3858574 Page Jan 1975 A
3878967 Joslin et al. Apr 1975 A
3910257 Fletcher et al. Oct 1975 A
3910260 Sarnoff et al. Nov 1975 A
3921196 Patterson Nov 1975 A
3971000 Cromwell Jul 1976 A
3995630 Verrdonk Dec 1976 A
3998103 Bjorklund et al. Dec 1976 A
4032908 Rice et al. Jun 1977 A
4078562 Friedman Mar 1978 A
4144496 Cunningham et al. Mar 1979 A
4151407 McBride et al. Apr 1979 A
4156867 Bench et al. May 1979 A
4164320 Irazoqui et al. Aug 1979 A
4173971 Karz Nov 1979 A
4199307 Jassawalla Apr 1980 A
4270532 Franetzki et al. Jun 1981 A
4273121 Jassawalla Jun 1981 A
4282872 Franetzki et al. Aug 1981 A
4308866 Jelliffe et al. Jan 1982 A
4319338 Grudowski et al. Mar 1982 A
4320757 Whitney et al. Mar 1982 A
4354252 Lamb et al. Oct 1982 A
4369780 Sakai Jan 1983 A
4370983 Lichtenstein Feb 1983 A
4373527 Fischell Feb 1983 A
4381776 Latham, Jr. May 1983 A
4385630 Gilcher et al. May 1983 A
4398289 Schoate Aug 1983 A
4398908 Siposs Aug 1983 A
4414566 Peyton et al. Nov 1983 A
4416654 Schoendorfer et al. Nov 1983 A
4425114 Schoendorfer et al. Jan 1984 A
4428381 Hepp Jan 1984 A
4443216 Chappell Apr 1984 A
4447224 DeCant, Jr. et al. May 1984 A
4449538 Corbitt et al. May 1984 A
4451255 Bujan et al. May 1984 A
4457750 Hill Jul 1984 A
4458693 Badzinski et al. Jul 1984 A
4460358 Somerville et al. Jul 1984 A
4464172 Lichtenstein Aug 1984 A
4469481 Kobayashi Sep 1984 A
4475901 Kraegen et al. Oct 1984 A
4476381 Rubin Oct 1984 A
4480751 Lueptow Nov 1984 A
4481670 Freeburg Nov 1984 A
4487604 Iwatschenko et al. Dec 1984 A
4490798 Franks et al. Dec 1984 A
4496351 Hillel et al. Jan 1985 A
4511352 Theeuwes et al. Apr 1985 A
4525861 Freeburg Jun 1985 A
4529401 Leslie et al. Jul 1985 A
4531527 Reinhold, Jr. et al. Jul 1985 A
4538138 Harvey et al. Aug 1985 A
4545071 Freeburg Oct 1985 A
4551133 Zegers de Beyl et al. Nov 1985 A
4559038 Berg et al. Dec 1985 A
4560979 Rosskopf Dec 1985 A
4561443 Hogrefe et al. Dec 1985 A
4562751 Nason Jan 1986 A
4564054 Gustavsson Jan 1986 A
4590473 Burke et al. May 1986 A
4602249 Abbott Jul 1986 A
4619653 Fischell Oct 1986 A
4622979 Katchis et al. Nov 1986 A
4624661 Arimond Nov 1986 A
4636950 Caswell et al. Jan 1987 A
4637817 Archibald et al. Jan 1987 A
4650469 Berg et al. Mar 1987 A
4652262 Veracchi Mar 1987 A
4653010 Figler et al. Mar 1987 A
4676776 Howson Jun 1987 A
4681563 Deckert et al. Jul 1987 A
4688167 Agarwal Aug 1987 A
4691580 Fosslien Sep 1987 A
4695954 Rose et al. Sep 1987 A
4696671 Epstein et al. Sep 1987 A
4697928 Csongor Oct 1987 A
4702595 Mutschler et al. Oct 1987 A
4705506 Archibald Nov 1987 A
D293135 Medema et al. Dec 1987 S
4714462 DiComenico Dec 1987 A
4717042 McLaughlin Jan 1988 A
4718576 Tamura et al. Jan 1988 A
4722224 Scheller et al. Feb 1988 A
4722349 Baumberg Feb 1988 A
4722734 Kolln Feb 1988 A
4730849 Siegel Mar 1988 A
4731058 Doan Mar 1988 A
4732411 Siegel Mar 1988 A
4741732 Crankshaw et al. May 1988 A
4741736 Brown May 1988 A
4756706 Kerns et al. Jul 1988 A
4759756 Forman Jul 1988 A
4778449 Weber et al. Oct 1988 A
4779626 Peel et al. Oct 1988 A
4784645 Fischell Nov 1988 A
4785799 Schoon et al. Nov 1988 A
4785969 McLaughlin Nov 1988 A
4796644 Polaschegg Jan 1989 A
4797840 Fraden Jan 1989 A
4803625 Fu et al. Feb 1989 A
4810090 Boucher Mar 1989 A
4810243 Howson Mar 1989 A
4811844 Moulding, Jr. et al. Mar 1989 A
4816208 Woods et al. Mar 1989 A
4817044 Ogren Mar 1989 A
4828545 Epstein et al. May 1989 A
4829524 Yoshida May 1989 A
4830018 Treach May 1989 A
4831562 Mcintosh et al. May 1989 A
4832033 Maher et al. May 1989 A
4835372 Gombrich et al. May 1989 A
4835521 Andrejasich et al. May 1989 A
4838275 Lee Jun 1989 A
4839806 Goldfischer et al. Jun 1989 A
4845644 Anthias et al. Jul 1989 A
4847764 Halvorson Jul 1989 A
4850009 Zook et al. Jul 1989 A
4850972 Schulman et al. Jul 1989 A
4853521 Claeys et al. Aug 1989 A
4854324 Hirschman et al. Aug 1989 A
4857713 Brown Aug 1989 A
4857716 Gombrich et al. Aug 1989 A
4865584 Epstein et al. Sep 1989 A
4871351 Feingold Oct 1989 A
4878175 Norden-Paul et al. Oct 1989 A
4889132 Hutcheson et al. Dec 1989 A
4889134 Wold et al. Dec 1989 A
4893270 Beck et al. Jan 1990 A
4897777 Janke et al. Jan 1990 A
4898209 Zbed Feb 1990 A
4898576 Philip Feb 1990 A
4898578 Rubalcaba, Jr. Feb 1990 A
4901728 Hutchison Feb 1990 A
4908017 Howson et al. Mar 1990 A
4912623 Rantala et al. Mar 1990 A
4916441 Gombrich et al. Apr 1990 A
4922922 Pollock et al. May 1990 A
4925444 Orkin et al. May 1990 A
4933843 Scheller et al. Jun 1990 A
4937777 Flood et al. Jun 1990 A
4941808 Qureshi et al. Jul 1990 A
4943279 Samiotes et al. Jul 1990 A
4946445 Lynn Aug 1990 A
4949274 Hollander et al. Aug 1990 A
4952928 Carroll et al. Aug 1990 A
4953074 Kametani et al. Aug 1990 A
4960230 Marelli Oct 1990 A
4966579 Polaschegg Oct 1990 A
4967928 Carter Nov 1990 A
4968295 Neumann Nov 1990 A
4977590 Milovancevic Dec 1990 A
4978335 Arthur, III Dec 1990 A
4991091 Allen Feb 1991 A
4992926 Janke et al. Feb 1991 A
4993068 Piosenka et al. Feb 1991 A
4993506 Angel Feb 1991 A
4998249 Bennett et al. Mar 1991 A
5002055 Merki et al. Mar 1991 A
5003296 Lee Mar 1991 A
5006699 Felkner et al. Apr 1991 A
5007429 Treatch et al. Apr 1991 A
5012402 Akiyama Apr 1991 A
5012411 Policastro et al. Apr 1991 A
5014875 McLaughlin et al. May 1991 A
5016172 Dessertine May 1991 A
5023770 Siverling Jun 1991 A
5025374 Roizen et al. Jun 1991 A
5036852 Leishman Aug 1991 A
5038800 Oba Aug 1991 A
5041086 Koenig et al. Aug 1991 A
5045048 Kaleskas et al. Sep 1991 A
5047959 Phillips et al. Sep 1991 A
5053031 Borsanyi Oct 1991 A
5053990 Kreifels et al. Oct 1991 A
5055001 Natwick et al. Oct 1991 A
5057076 Polaschegg Oct 1991 A
5061243 Winchell et al. Oct 1991 A
5072356 Watt et al. Dec 1991 A
5072383 Brimm et al. Dec 1991 A
5072412 Henderson, Jr. et al. Dec 1991 A
5078683 Sancoff et al. Jan 1992 A
5084828 Kaufman et al. Jan 1992 A
5087245 Doan Feb 1992 A
5088904 Okada Feb 1992 A
5088981 Howson et al. Feb 1992 A
5088990 Hivale et al. Feb 1992 A
5096385 Georgi et al. Mar 1992 A
5098377 Borsanyi et al. Mar 1992 A
5100380 Epstein et al. Mar 1992 A
5100394 Dudar et al. Mar 1992 A
5104374 Bishko et al. Apr 1992 A
5108363 Tuttle et al. Apr 1992 A
5108367 Epstein et al. Apr 1992 A
5108372 Swenson Apr 1992 A
5109487 Ohgomori et al. Apr 1992 A
5109849 Goodman et al. May 1992 A
5112319 Lai May 1992 A
5116203 Natwick et al. May 1992 A
5116312 Blankenship et al. May 1992 A
5131092 Sackmann et al. Jul 1992 A
5134574 Beaverstock et al. Jul 1992 A
5135500 Zdeb Aug 1992 A
5137023 Mendelson et al. Aug 1992 A
5151978 Bronikowski et al. Sep 1992 A
5152296 Simons Oct 1992 A
5153416 Neeley Oct 1992 A
5153827 Coutre et al. Oct 1992 A
5155693 Altmayer et al. Oct 1992 A
5157595 Lovrenich Oct 1992 A
5158091 Butterfield et al. Oct 1992 A
5159673 Sackmann et al. Oct 1992 A
5160320 Yum et al. Nov 1992 A
5161211 Taguchi et al. Nov 1992 A
5167235 Seacord et al. Dec 1992 A
5169642 Brinker et al. Dec 1992 A
5172698 Stanko Dec 1992 A
5176004 Gaudet Jan 1993 A
5179569 Sawyer Jan 1993 A
5179700 Aihara et al. Jan 1993 A
5181910 Scanlon Jan 1993 A
5190185 Blechl Mar 1993 A
5190522 Wojcicki et al. Mar 1993 A
5191891 Righter Mar 1993 A
5208762 Charhut et al. May 1993 A
5208907 Shelton et al. May 1993 A
5211849 Kitaevich et al. May 1993 A
5213099 Tripp, Jr. May 1993 A
5213232 Kraft et al. May 1993 A
5213568 Lattin et al. May 1993 A
5219330 Bollish et al. Jun 1993 A
5219331 Vanderveen Jun 1993 A
5225974 Mathews et al. Jul 1993 A
5226425 Righter Jul 1993 A
5228450 Sellers Jul 1993 A
5231990 Gauglitz Aug 1993 A
5234404 Tuttle et al. Aug 1993 A
5235510 Yamada et al. Aug 1993 A
5236416 McDaniel et al. Aug 1993 A
5238001 Gallant et al. Aug 1993 A
5240007 Pytel et al. Aug 1993 A
5244463 Cordner, Jr. et al. Sep 1993 A
5245704 Weber et al. Sep 1993 A
5254096 Rondelet et al. Oct 1993 A
5256156 Kern et al. Oct 1993 A
5256157 Samiotes et al. Oct 1993 A
5265010 Evans-Paganelli et al. Nov 1993 A
5265431 Gaudet et al. Nov 1993 A
5267174 Kaufman et al. Nov 1993 A
5271405 Boyer et al. Dec 1993 A
5272318 Gorman Dec 1993 A
5272321 Otsuka et al. Dec 1993 A
5273517 Barone et al. Dec 1993 A
5277188 Selker Jan 1994 A
5283861 Dangler et al. Feb 1994 A
5284150 Butterfield et al. Feb 1994 A
5286252 Tuttle et al. Feb 1994 A
5292029 Pearson Mar 1994 A
5297257 Struger et al. Mar 1994 A
5298021 Sherer Mar 1994 A
5304126 Epstein et al. Apr 1994 A
5307263 Brown Apr 1994 A
5307372 Sawyer et al. Apr 1994 A
5307463 Hyatt et al. Apr 1994 A
5311908 Barone et al. May 1994 A
5314243 McDonald et al. May 1994 A
5315505 Pratt et al. May 1994 A
5317506 Coutre et al. May 1994 A
5319363 Welch et al. Jun 1994 A
5319543 Wilhelm Jun 1994 A
5321618 Gessman Jun 1994 A
5321829 Zifferer Jun 1994 A
5324422 Colleran et al. Jun 1994 A
5325478 Shelton et al. Jun 1994 A
5327341 Whalen et al. Jul 1994 A
5331549 Crawford, Jr. Jul 1994 A
5336245 Adams et al. Aug 1994 A
5337230 Baumgartner et al. Aug 1994 A
5337919 Spaulding et al. Aug 1994 A
5338157 Blomquist Aug 1994 A
5339421 Housel, III Aug 1994 A
5339821 Fujimoto Aug 1994 A
5341291 Roizen et al. Aug 1994 A
5341412 Ramot et al. Aug 1994 A
5348008 Bomn et al. Sep 1994 A
5348539 Herskowitz Sep 1994 A
5349675 Fitzgerald et al. Sep 1994 A
5356378 Doan Oct 1994 A
5361202 Doue Nov 1994 A
5361758 Hall et al. Nov 1994 A
5366896 Margrey et al. Nov 1994 A
5366904 Qureshi et al. Nov 1994 A
5367555 Isoyama Nov 1994 A
5368562 Blomguist et al. Nov 1994 A
5370612 Maeda et al. Dec 1994 A
5371687 Holmes, II et al. Dec 1994 A
5374251 Smith Dec 1994 A
5374813 Shipp Dec 1994 A
5374965 Kanno Dec 1994 A
5375604 Kelly et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5377864 Blechl et al. Jan 1995 A
5378231 Johnson et al. Jan 1995 A
5379214 Arbuckle et al. Jan 1995 A
5389078 Zalesky et al. Feb 1995 A
5390238 Kirk et al. Feb 1995 A
5392951 Gardner et al. Feb 1995 A
5395320 Padda et al. Mar 1995 A
5395321 Kawahara et al. Mar 1995 A
5398336 Tantry et al. Mar 1995 A
5401059 Ferrario Mar 1995 A
5404292 Hendrickson Apr 1995 A
5404384 Colburn et al. Apr 1995 A
5406473 Yoshikura et al. Apr 1995 A
5412715 Volpe May 1995 A
5415167 Wilk May 1995 A
5416695 Stutman et al. May 1995 A
5417222 Dempsey et al. May 1995 A
5420977 Sztipanovits et al. May 1995 A
5421343 Feng Jun 1995 A
5423746 Burkett et al. Jun 1995 A
5429602 Hauser Jul 1995 A
5431201 Torchia et al. Jul 1995 A
5431299 Brewer et al. Jul 1995 A
5431627 Pastrone et al. Jul 1995 A
5433736 Nilsson Jul 1995 A
5438607 Przygoda, Jr. et al. Aug 1995 A
5440699 Farrand et al. Aug 1995 A
5441047 David et al. Aug 1995 A
5445294 Gardner et al. Aug 1995 A
5445621 Poli et al. Aug 1995 A
5446868 Gardea, II et al. Aug 1995 A
5453098 Botts et al. Sep 1995 A
5455851 Chaco et al. Oct 1995 A
5458123 Unger Oct 1995 A
5460294 Williams Oct 1995 A
5460605 Tuttle et al. Oct 1995 A
5461665 Shur et al. Oct 1995 A
5462051 Oka et al. Oct 1995 A
5464392 Epstein et al. Nov 1995 A
5465286 Clare et al. Nov 1995 A
5467773 Bergelson et al. Nov 1995 A
5468110 McDonald et al. Nov 1995 A
5469855 Pompei et al. Nov 1995 A
5471382 Tallman et al. Nov 1995 A
5474552 Palti Dec 1995 A
5482043 Zulauf Jan 1996 A
5482446 Williamson et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5490610 Pearson Feb 1996 A
5494592 Latham, Jr. et al. Feb 1996 A
5496265 Langley et al. Mar 1996 A
5496273 Pastrone et al. Mar 1996 A
5502944 Kraft et al. Apr 1996 A
5507412 Ebert et al. Apr 1996 A
5508912 Schneiderman Apr 1996 A
5509318 Gomes Apr 1996 A
5509422 Fukami Apr 1996 A
5513957 O'Leary May 1996 A
5514088 Zakko May 1996 A
5514095 Brightbill et al. May 1996 A
5515426 Yacenda et al. May 1996 A
5520450 Colson, Jr. et al. May 1996 A
5520637 Pager et al. May 1996 A
5522396 Langer et al. Jun 1996 A
5522798 Johnson et al. Jun 1996 A
5526428 Arnold Jun 1996 A
5528503 Moore et al. Jun 1996 A
5529063 Hill Jun 1996 A
5531680 Dumas et al. Jul 1996 A
5531697 Olsen et al. Jul 1996 A
5531698 Olsen Jul 1996 A
5533079 Colburn et al. Jul 1996 A
5533981 Mandro et al. Jul 1996 A
5534691 Away et al. Jul 1996 A
5536084 Curtis et al. Jul 1996 A
5537313 Pirelli Jul 1996 A
5537853 Finburgh et al. Jul 1996 A
5542420 Goldman et al. Aug 1996 A
5544649 David et al. Aug 1996 A
5544651 Wilk Aug 1996 A
5544661 Davis et al. Aug 1996 A
5545140 Conero et al. Aug 1996 A
5546580 Seliger et al. Aug 1996 A
5547470 Johnson et al. Aug 1996 A
5549117 Tacklind et al. Aug 1996 A
5549460 O'Leary Aug 1996 A
5553609 Chen et al. Sep 1996 A
5558638 Evers et al. Sep 1996 A
5558640 Pfeiler et al. Sep 1996 A
5560352 Heim et al. Oct 1996 A
5562232 Pearson Oct 1996 A
5562621 Claude et al. Oct 1996 A
5563347 Martin et al. Oct 1996 A
5564803 McDonald et al. Oct 1996 A
5568912 Minami et al. Oct 1996 A
5569186 Lord et al. Oct 1996 A
5569187 Kaiser Oct 1996 A
5571258 Pearson Nov 1996 A
5573502 LeCocq et al. Nov 1996 A
5573506 Vasko Nov 1996 A
5575632 Morris et al. Nov 1996 A
5576952 Stutman et al. Nov 1996 A
5579001 Dempsey et al. Nov 1996 A
5579378 Arlinghaus, Jr. Nov 1996 A
5581369 Righter et al. Dec 1996 A
5581687 Lyle et al. Dec 1996 A
5582593 Hultman Dec 1996 A
5583758 Mcilroy et al. Dec 1996 A
5588815 Zaleski, II Dec 1996 A
5589932 Garcia-Rubio et al. Dec 1996 A
5590648 Mitchell et al. Jan 1997 A
5593267 McDonald et al. Jan 1997 A
5594637 Eisenberg et al. Jan 1997 A
5594786 Chaco et al. Jan 1997 A
5597995 Williams et al. Jan 1997 A
5598536 Slaughter, III et al. Jan 1997 A
5601445 Schipper et al. Feb 1997 A
5609575 Larson et al. Mar 1997 A
5609576 Voss et al. Mar 1997 A
5613115 Gihl et al. Mar 1997 A
5619428 Lee et al. Apr 1997 A
5619991 Sloane Apr 1997 A
5623652 Vora et al. Apr 1997 A
5623925 Swenson et al. Apr 1997 A
5626144 Tacklind et al. May 1997 A
5628619 Wilson May 1997 A
5630710 Tune et al. May 1997 A
5631844 Margrey et al. May 1997 A
5633910 Cohen May 1997 A
D380260 Hyman Jun 1997 S
5634893 Rishton Jun 1997 A
5637082 Pages et al. Jun 1997 A
5637093 Hyman et al. Jun 1997 A
5640301 Roecher et al. Jun 1997 A
5640953 Bishop et al. Jun 1997 A
5641628 Bianchi Jun 1997 A
5643193 Papillon et al. Jul 1997 A
5643212 Coutre et al. Jul 1997 A
5647853 Feldmann et al. Jul 1997 A
5647854 Olsen et al. Jul 1997 A
5651775 Walker et al. Jul 1997 A
5652566 Lambert Jul 1997 A
5658240 Urdahl et al. Aug 1997 A
5658250 Blomguist et al. Aug 1997 A
5661978 Holmes et al. Sep 1997 A
5664270 Bell et al. Sep 1997 A
5666404 Ciccotelli et al. Sep 1997 A
D385646 Chan Oct 1997 S
5678562 Sellers Oct 1997 A
5678568 Uchikubo et al. Oct 1997 A
5681285 Ford et al. Oct 1997 A
5682526 Smokoff et al. Oct 1997 A
5683367 Jordan et al. Nov 1997 A
5685844 Marttila Nov 1997 A
5687717 Halpern Nov 1997 A
5687734 Dempsey et al. Nov 1997 A
5695473 Olsen Dec 1997 A
5697951 Harpstead Dec 1997 A
5700998 Palti Dec 1997 A
5701894 Cherry et al. Dec 1997 A
5704351 Mortara et al. Jan 1998 A
5704364 Saltzstein et al. Jan 1998 A
5704366 Tacklind et al. Jan 1998 A
5712798 Langley et al. Jan 1998 A
5712912 Tomko et al. Jan 1998 A
5713485 Liff et al. Feb 1998 A
5713856 Eggers et al. Feb 1998 A
5715823 Wood et al. Feb 1998 A
5716114 Holmes et al. Feb 1998 A
5716194 Butterfield et al. Feb 1998 A
5718562 Lawless et al. Feb 1998 A
5719761 Gatti et al. Feb 1998 A
RE35743 Pearson Mar 1998 E
5724025 Tavori Mar 1998 A
5724580 Levin et al. Mar 1998 A
5732709 Tacklind et al. Mar 1998 A
5733259 Valcke et al. Mar 1998 A
5735887 Barreras, Sr. et al. Apr 1998 A
5737539 Edelson et al. Apr 1998 A
5740185 Bosse Apr 1998 A
5740800 Hendrickson et al. Apr 1998 A
5745366 Higham et al. Apr 1998 A
5745378 Barker et al. Apr 1998 A
5752917 Fuchs May 1998 A
5752976 Duffin et al. May 1998 A
5755563 Clegg et al. May 1998 A
5758095 Albaum et al. May 1998 A
5764923 Tallman et al. Jun 1998 A
5766155 Hyman et al. Jun 1998 A
5769811 Stacey et al. Jun 1998 A
5771657 Lasher et al. Jun 1998 A
5772585 Lavin et al. Jun 1998 A
5772586 Heinonen et al. Jun 1998 A
5772635 Dastur et al. Jun 1998 A
5772637 Heinzmann et al. Jun 1998 A
5776057 Swenson et al. Jul 1998 A
5778345 McCartney Jul 1998 A
5778882 Raymond et al. Jul 1998 A
5781442 Engleson et al. Jul 1998 A
5782805 Meinzer et al. Jul 1998 A
5782878 Morgan et al. Jul 1998 A
5785650 Akasaka et al. Jul 1998 A
5788669 Peterson Aug 1998 A
5790409 Fedor et al. Aug 1998 A
5791342 Woodard Aug 1998 A
5791880 Wilson Aug 1998 A
5793861 Haigh Aug 1998 A
5793969 Kamentsky et al. Aug 1998 A
5795317 Brierton et al. Aug 1998 A
5795327 Wilson et al. Aug 1998 A
5797515 Liff et al. Aug 1998 A
5800387 Duffy et al. Sep 1998 A
5801755 Echerer Sep 1998 A
5803906 Pratt et al. Sep 1998 A
5805442 Crater et al. Sep 1998 A
5805454 Valerino et al. Sep 1998 A
5805456 Higham et al. Sep 1998 A
5805505 Zheng et al. Sep 1998 A
5807321 Stoker et al. Sep 1998 A
5807322 Lindsey et al. Sep 1998 A
5807336 Russo et al. Sep 1998 A
5810747 Brudny et al. Sep 1998 A
5812410 Lion et al. Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5815566 Ramot et al. Sep 1998 A
5818528 Roth et al. Oct 1998 A
5822418 Yacenda et al. Oct 1998 A
5822544 Chaco et al. Oct 1998 A
5823949 Goltra Oct 1998 A
5826237 Macrae et al. Oct 1998 A
5829438 Gibbs et al. Nov 1998 A
5832447 Rieker et al. Nov 1998 A
5832448 Brown Nov 1998 A
5832450 Myers et al. Nov 1998 A
5833599 Schrier et al. Nov 1998 A
5841975 Layne et al. Nov 1998 A
5842841 Danby et al. Dec 1998 A
5842976 Williamson Dec 1998 A
5845253 Rensimer et al. Dec 1998 A
5848593 McGrady et al. Dec 1998 A
5851186 Wood et al. Dec 1998 A
5852590 De La Huerga Dec 1998 A
5853387 Clegg et al. Dec 1998 A
5855550 Lai et al. Jan 1999 A
5857967 Frid et al. Jan 1999 A
5859972 Subramaniam et al. Jan 1999 A
5865745 Schmitt et al. Feb 1999 A
5865786 Sibalis et al. Feb 1999 A
5867821 Ballantyne et al. Feb 1999 A
5871465 Vasko Feb 1999 A
5876926 Beecham Mar 1999 A
5880443 McDonald et al. Mar 1999 A
5882338 Gray Mar 1999 A
5883370 Walker et al. Mar 1999 A
5883576 De La Huerga Mar 1999 A
5884273 Sattizahn et al. Mar 1999 A
5884457 Ortiz et al. Mar 1999 A
5885245 Lynch et al. Mar 1999 A
5891035 Wood et al. Apr 1999 A
5891734 Gill et al. Apr 1999 A
5893697 Zimi et al. Apr 1999 A
5894273 Meador et al. Apr 1999 A
5895371 Levitas et al. Apr 1999 A
5897493 Brown Apr 1999 A
5897530 Jackson Apr 1999 A
5897989 Beecham Apr 1999 A
5899665 Makino et al. May 1999 A
5899855 Brown May 1999 A
5901150 Jhuboo et al. May 1999 A
5904668 Hyman et al. May 1999 A
5905653 Higham et al. May 1999 A
5907291 Chen et al. May 1999 A
5907493 Boyer et al. May 1999 A
5908027 Butterfield et al. Jun 1999 A
5910107 Iliff Jun 1999 A
5910252 Truitt et al. Jun 1999 A
5911132 Sloane Jun 1999 A
5911687 Sato et al. Jun 1999 A
5912818 McGrady et al. Jun 1999 A
5913197 Kameda Jun 1999 A
5913310 Brown Jun 1999 A
5915089 Stevens et al. Jun 1999 A
5915240 Karpf Jun 1999 A
5919154 Toavs et al. Jul 1999 A
5921938 Aoyama et al. Jul 1999 A
5923018 Kameda et al. Jul 1999 A
5924074 Evans Jul 1999 A
5924103 Ahmed et al. Jul 1999 A
5927540 Godlewski Jul 1999 A
5931791 Saltzstein et al. Aug 1999 A
5935060 Iliff Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
5938413 Makino et al. Aug 1999 A
5939326 Chupp et al. Aug 1999 A
5939699 Perttunen et al. Aug 1999 A
5940306 Gardner et al. Aug 1999 A
5940802 Hildebrand et al. Aug 1999 A
5941829 Saltzstein et al. Aug 1999 A
5942986 Shabot et al. Aug 1999 A
5943423 Muftic Aug 1999 A
5943633 Wilson et al. Aug 1999 A
5944659 Flach et al. Aug 1999 A
5945651 Chorosinski et al. Aug 1999 A
5946083 Melendez et al. Aug 1999 A
5946659 Lancelot et al. Aug 1999 A
D414578 Chen et al. Sep 1999 S
5950006 Crater et al. Sep 1999 A
5951300 Brown Sep 1999 A
5951510 Barak Sep 1999 A
5954640 Szabo Sep 1999 A
5954885 Bollish et al. Sep 1999 A
5954971 Pages et al. Sep 1999 A
5956023 Lyle et al. Sep 1999 A
5957885 Bollish et al. Sep 1999 A
5959529 Kail, IV Sep 1999 A
5960085 de la Huerga Sep 1999 A
5960403 Brown Sep 1999 A
5960991 Ophardt Oct 1999 A
5961446 Beller et al. Oct 1999 A
5961448 Swenson et al. Oct 1999 A
5961487 Davis Oct 1999 A
5963641 Crandall et al. Oct 1999 A
5964700 Tallman et al. Oct 1999 A
5966304 Cook et al. Oct 1999 A
5967975 Ridgeway Oct 1999 A
5970423 Langley et al. Oct 1999 A
5971593 McGrady Oct 1999 A
5971921 Timbel Oct 1999 A
5971948 Pages et al. Oct 1999 A
5974124 Schlueter, Jr. et al. Oct 1999 A
5975737 Crater et al. Nov 1999 A
5980490 Tsoukalis Nov 1999 A
5983193 Heinonen et al. Nov 1999 A
5987519 Peifer et al. Nov 1999 A
5991731 Colon et al. Nov 1999 A
5993046 McGrady et al. Nov 1999 A
5993420 Hyman et al. Nov 1999 A
5995077 Wilcox et al. Nov 1999 A
5995965 Experton Nov 1999 A
5997167 Crater et al. Dec 1999 A
5997476 Brown Dec 1999 A
6003006 Colella et al. Dec 1999 A
6004020 Bartur Dec 1999 A
6004276 Wright et al. Dec 1999 A
6006191 DeRienzo Dec 1999 A
6006946 Williams Dec 1999 A
6009333 Chaco Dec 1999 A
6010454 Arieff Jan 2000 A
6011858 Stock et al. Jan 2000 A
6011999 Holmes Jan 2000 A
6012034 Hamparian et al. Jan 2000 A
6013057 Danby et al. Jan 2000 A
6014631 Teagarden et al. Jan 2000 A
6016444 John Jan 2000 A
6017318 Gauthier et al. Jan 2000 A
6018713 Coli et al. Jan 2000 A
6019745 Gray Feb 2000 A
6021392 Lester et al. Feb 2000 A
6022315 Iliff Feb 2000 A
6023522 Off et al. Feb 2000 A
6024539 Blomquist Feb 2000 A
6024699 Surwit et al. Feb 2000 A
6027217 McClure et al. Feb 2000 A
6029138 Khorasani et al. Feb 2000 A
6032119 Brown et al. Feb 2000 A
6032155 de la Huerga Feb 2000 A
6033076 Braeuning et al. Mar 2000 A
6039251 Holowko et al. Mar 2000 A
6039467 Holmes Mar 2000 A
6047259 Campbell et al. Apr 2000 A
6048086 Valerino Apr 2000 A
6050940 Braun et al. Apr 2000 A
6055487 Margery et al. Apr 2000 A
6057758 Dempsey et al. May 2000 A
6059736 Tapper May 2000 A
6061603 Papadopoulos et al. May 2000 A
6065819 Holmes et al. May 2000 A
6068153 Young et al. May 2000 A
6068156 Liff et al. May 2000 A
6073046 Patel et al. Jun 2000 A
6074345 van Oostrom et al. Jun 2000 A
6079621 Vardanyan et al. Jun 2000 A
6080106 Lloyd et al. Jun 2000 A
6081048 Bergmann et al. Jun 2000 A
6082776 Feinberg Jul 2000 A
6083206 Molko Jul 2000 A
6093146 Filangeri Jul 2000 A
6095985 Raymond Aug 2000 A
6096561 Tayi Aug 2000 A
6098892 Peoples, Jr. Aug 2000 A
6101407 Groezinger Aug 2000 A
6101478 Brown Aug 2000 A
6102856 Groff et al. Aug 2000 A
6108399 Hernandez-Guerra et al. Aug 2000 A
6108588 McGrady Aug 2000 A
6109774 Holmes et al. Aug 2000 A
6112224 Peifer et al. Aug 2000 A
RE36871 Epstein et al. Sep 2000 E
6113554 Gilcher et al. Sep 2000 A
6116461 Broadfield et al. Sep 2000 A
6117940 Mjalli Sep 2000 A
6123524 Danby et al. Sep 2000 A
6125350 Dirbas Sep 2000 A
6129517 Danby et al. Oct 2000 A
6132371 Dempsey et al. Oct 2000 A
6134504 Douglas et al. Oct 2000 A
6135949 Russo et al. Oct 2000 A
6139495 De La Huerga Oct 2000 A
6141412 Smith et al. Oct 2000 A
6144922 Douglas et al. Nov 2000 A
6145695 Garrigues Nov 2000 A
6146523 Kenley et al. Nov 2000 A
6148297 Swor et al. Nov 2000 A
6149063 Reynolds et al. Nov 2000 A
6151536 Arnold et al. Nov 2000 A
6152364 Schoonen et al. Nov 2000 A
6154668 Pedersen et al. Nov 2000 A
6154726 Rensimer et al. Nov 2000 A
6157914 Seto et al. Dec 2000 A
6158965 Butterfield et al. Dec 2000 A
6160478 Jacobsen et al. Dec 2000 A
6161095 Brown Dec 2000 A
6161141 Dillon Dec 2000 A
6163737 Fedor et al. Dec 2000 A
6165154 Gray et al. Dec 2000 A
6168563 Brown Jan 2001 B1
6170007 Venkatraman et al. Jan 2001 B1
6170746 Brook et al. Jan 2001 B1
6171112 Clark et al. Jan 2001 B1
6171237 Avitall et al. Jan 2001 B1
6171264 Bader Jan 2001 B1
6173198 Schulze et al. Jan 2001 B1
6175779 Barrett Jan 2001 B1
6175977 Schumacher et al. Jan 2001 B1
6176392 William et al. Jan 2001 B1
6182047 Dirbas Jan 2001 B1
6183417 Geheb et al. Feb 2001 B1
6186145 Brown Feb 2001 B1
6192320 Margrey et al. Feb 2001 B1
6193480 Butterfield Feb 2001 B1
6195887 Danby et al. Mar 2001 B1
6198394 Jacobsen et al. Mar 2001 B1
6200264 Satherley et al. Mar 2001 B1
6200289 Hochman et al. Mar 2001 B1
6202923 Boyer et al. Mar 2001 B1
6203495 Bardy Mar 2001 B1
6203528 Deckert et al. Mar 2001 B1
6206238 Ophardt Mar 2001 B1
6206829 Iliff Mar 2001 B1
6210361 Kamen et al. Apr 2001 B1
6213391 Lewis Apr 2001 B1
6213738 Danby et al. Apr 2001 B1
6219439 Burger Apr 2001 B1
6219587 Ahlin et al. Apr 2001 B1
6221011 Bardy Apr 2001 B1
6221012 Maschke et al. Apr 2001 B1
6222619 Herron et al. Apr 2001 B1
6224549 Drongelen May 2001 B1
6225901 Kail, IV May 2001 B1
6226564 Stuart May 2001 B1
6226745 Wiederhold May 2001 B1
6230927 Schoonen et al. May 2001 B1
6234997 Kamen et al. May 2001 B1
6245013 Minoz et al. Jun 2001 B1
6246473 Smith, Jr. et al. Jun 2001 B1
6248063 Barnhill et al. Jun 2001 B1
6248065 Brown Jun 2001 B1
6255951 De La Huerga Jul 2001 B1
6256643 Cork et al. Jul 2001 B1
6256967 Hebron et al. Jul 2001 B1
6259355 Chaco et al. Jul 2001 B1
6259654 De La Huerga Jul 2001 B1
6266645 Simpson Jul 2001 B1
6269340 Ford et al. Jul 2001 B1
D446854 Cheney, II et al. Aug 2001 S
6270455 Brown Aug 2001 B1
6270457 Bardy Aug 2001 B1
6272394 Lipps Aug 2001 B1
6272505 De La Huerga Aug 2001 B1
6277072 Bardy Aug 2001 B1
6283322 Liff et al. Sep 2001 B1
6283944 McMullen et al. Sep 2001 B1
6290646 Cosentino et al. Sep 2001 B1
6290650 Butterfield et al. Sep 2001 B1
6294999 Yarin et al. Sep 2001 B1
6295506 Heinonen Sep 2001 B1
6304788 Eady et al. Oct 2001 B1
6306088 Krausman et al. Oct 2001 B1
6307956 Black Oct 2001 B1
6308171 De La Huerga Oct 2001 B1
6311163 Sheehan et al. Oct 2001 B1
6312227 Davis Nov 2001 B1
6312378 Bardy Nov 2001 B1
6314384 Goetz Nov 2001 B1
6317719 Schrier et al. Nov 2001 B1
6319200 Lai et al. Nov 2001 B1
6321203 Kameda Nov 2001 B1
6322504 Kirshner Nov 2001 B1
6322515 Goor et al. Nov 2001 B1
6330491 Lion Dec 2001 B1
RE37531 Chaco et al. Jan 2002 E
6337631 Pai et al. Jan 2002 B1
6338007 Broadfield et al. Jan 2002 B1
6339732 Phoon et al. Jan 2002 B1
6345260 Cummings, Jr. et al. Feb 2002 B1
6346886 De La Huerga Feb 2002 B1
6352200 Schoonen et al. Mar 2002 B1
6353817 Jacobs et al. Mar 2002 B1
6358225 Butterfield Mar 2002 B1
6358237 Paukovits et al. Mar 2002 B1
6361263 Dewey et al. Mar 2002 B1
6362591 Moberg Mar 2002 B1
6363282 Nichols et al. Mar 2002 B1
6363290 Lyle et al. Mar 2002 B1
6364834 Reuss et al. Apr 2002 B1
6368273 Brown Apr 2002 B1
6370841 Chudy et al. Apr 2002 B1
6381577 Brown Apr 2002 B1
6385505 Lipps May 2002 B1
6393369 Carr May 2002 B1
6397190 Goetz May 2002 B1
6402702 Gilcher et al. Jun 2002 B1
6406426 Reuss et al. Jun 2002 B1
6407335 Franklin-Lees et al. Jun 2002 B1
6408330 DeLaHuerga Jun 2002 B1
6416471 Kumar et al. Jul 2002 B1
6421650 Goetz et al. Jul 2002 B1
6427088 Bowman, IV et al. Jul 2002 B1
6434531 Lancelot et al. Aug 2002 B1
6434569 Tomlinson et al. Aug 2002 B1
6438451 Lion Aug 2002 B1
RE37829 Charhut et al. Sep 2002 E
6449927 Hebron et al. Sep 2002 B2
6450956 Rappaport et al. Sep 2002 B1
6458102 Mann et al. Oct 2002 B1
6468242 Wilson et al. Oct 2002 B1
6470234 McGrady Oct 2002 B1
6471089 Liff et al. Oct 2002 B2
6471645 Warkentin et al. Oct 2002 B1
6475146 Frelburger et al. Nov 2002 B1
6475148 Jackson et al. Nov 2002 B1
6475180 Peterson et al. Nov 2002 B2
6478737 Bardy Nov 2002 B2
6485465 Moberg et al. Nov 2002 B2
6511138 Gardner et al. Jan 2003 B1
6519569 White et al. Feb 2003 B1
6537244 Paukovits Mar 2003 B2
6542902 Dulong et al. Apr 2003 B2
6542910 Cork et al. Apr 2003 B2
6544174 West et al. Apr 2003 B2
6544228 Heitmeier Apr 2003 B1
6551243 Bocionek et al. Apr 2003 B2
6551276 Mann et al. Apr 2003 B1
6554791 Cartledge et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6555986 Moberg Apr 2003 B2
6558321 Burd et al. May 2003 B1
6561975 Pool et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6564104 Nelson et al. May 2003 B2
6564105 Starkweather et al. May 2003 B2
6564121 Wallace et al. May 2003 B1
6571128 Lebel et al. May 2003 B2
6575900 Zweig et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6579232 Sakamaki et al. Jun 2003 B2
6581069 Robinson et al. Jun 2003 B1
6581798 Liff et al. Jun 2003 B2
6584336 Ali et al. Jun 2003 B1
6585157 Brandt et al. Jul 2003 B2
6585644 Lebel et al. Jul 2003 B2
6585675 O'Mahony et al. Jul 2003 B1
6592551 Cobb Jul 2003 B1
6593528 Franklin-Lees et al. Jul 2003 B2
6607485 Bardy Aug 2003 B2
6610973 Davis, III Aug 2003 B1
6613009 Bainbridge et al. Sep 2003 B1
6635014 Starkweather et al. Oct 2003 B2
6648821 Lebel et al. Nov 2003 B2
6659948 Lebel et al. Dec 2003 B2
6664893 Eveland et al. Dec 2003 B1
6668196 Villegas et al. Dec 2003 B1
6673314 Burbank et al. Jan 2004 B1
6687546 Lebel et al. Jan 2004 B2
6689091 Bui et al. Feb 2004 B2
6694191 Starkweather et al. Feb 2004 B2
6694334 DuLong et al. Feb 2004 B2
6711460 Reese Mar 2004 B1
6731324 Levy May 2004 B2
6733447 Lai et al. May 2004 B2
6735497 Wallace et al. May 2004 B2
6740075 Lebel et al. May 2004 B2
6746398 Hervy et al. Jun 2004 B2
6758810 Lebel et al. Jul 2004 B2
6768425 Flaherty et al. Jul 2004 B2
6771369 Rzasa et al. Aug 2004 B2
6775602 Gordon, Jr. et al. Aug 2004 B2
6776304 Liff et al. Aug 2004 B2
6790198 White et al. Sep 2004 B1
6804656 Rosenfeld et al. Oct 2004 B1
6810290 Lebel et al. Oct 2004 B2
6811533 Lebel et al. Nov 2004 B2
6811534 Bowman, IV et al. Nov 2004 B2
6811707 Rovatti et al. Nov 2004 B2
6813473 Broker Nov 2004 B1
6813519 Lebel et al. Nov 2004 B2
6814255 Liff et al. Nov 2004 B2
6820093 De La Huerga Nov 2004 B2
6842736 Brzozowski Jan 2005 B1
6847861 Lunak et al. Jan 2005 B2
6854088 Massengale et al. Feb 2005 B2
6871211 Labounty et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6877530 Osborne et al. Apr 2005 B2
6880034 Manke et al. Apr 2005 B2
6885288 Pincus Apr 2005 B2
6892941 Rosenblum May 2005 B2
6912549 Rotter et al. Jun 2005 B2
6913590 Sorenson et al. Jul 2005 B2
6915823 Osborne et al. Jul 2005 B2
6928452 De La Huerga Aug 2005 B2
6950708 Bowman, IV et al. Sep 2005 B2
6958705 Lebel et al. Oct 2005 B2
6974437 Lebel et al. Dec 2005 B2
6975924 Kircher et al. Dec 2005 B2
6976628 Krupa Dec 2005 B2
6979306 Moll Dec 2005 B2
6980958 Surwit et al. Dec 2005 B1
6981644 Cheong et al. Jan 2006 B2
6985870 Martucci et al. Jan 2006 B2
6991002 Osborne et al. Jan 2006 B2
6995664 Darling Feb 2006 B1
7006893 Hart et al. Feb 2006 B2
7015806 Naidoo et al. Mar 2006 B2
7017622 Osborne et al. Mar 2006 B2
7017623 Tribble et al. Mar 2006 B2
7028723 Alouani et al. Apr 2006 B1
7096212 Tribble et al. Aug 2006 B2
7117902 Osborne Oct 2006 B2
7151982 Liff et al. Dec 2006 B2
7194336 DiGianfilippo et al. Mar 2007 B2
7209891 Addy et al. Apr 2007 B1
7240699 Osborne et al. Jul 2007 B2
7277579 Huang Oct 2007 B2
7277757 Casavant et al. Oct 2007 B2
7317967 DiGianfilippo et al. Jan 2008 B2
7343224 DiGianfilippo et al. Mar 2008 B2
7403901 Carley et al. Jul 2008 B1
7427002 Liff et al. Sep 2008 B2
7493263 Helmus et al. Feb 2009 B2
7499581 Tribble et al. Mar 2009 B2
7555557 Bradley et al. Jun 2009 B2
7561312 Proudfoot et al. Jul 2009 B1
7581953 Lehmann et al. Sep 2009 B2
7599516 Limer et al. Oct 2009 B2
7610115 Rob et al. Oct 2009 B2
7630908 Amrien et al. Dec 2009 B1
7636718 Steen et al. Dec 2009 B1
7672859 Louie et al. Mar 2010 B1
7698019 Moncrief et al. Apr 2010 B2
7734478 Goodall et al. Jun 2010 B2
7753085 Tribble et al. Jul 2010 B2
7769601 Bleser et al. Aug 2010 B1
7783383 Eliuk et al. Aug 2010 B2
D624225 Federico et al. Sep 2010 S
7801642 Ansari et al. Sep 2010 B2
7847970 McGrady Dec 2010 B1
7853621 Guo Dec 2010 B2
7931859 Mlodzinski et al. Apr 2011 B2
7937290 Bahir May 2011 B2
7986369 Burns Jul 2011 B1
7991507 Liff et al. Aug 2011 B2
8170271 Chen May 2012 B2
8191339 Tribble et al. Jun 2012 B2
8215557 Reno et al. Jul 2012 B1
8220503 Tribble et al. Jul 2012 B2
8225824 Eliuk et al. Jul 2012 B2
D667961 Marmier Sep 2012 S
8267129 Doherty et al. Sep 2012 B2
8271138 Eliuk et al. Sep 2012 B2
8280549 Liff et al. Oct 2012 B2
8284305 Newcomb et al. Oct 2012 B2
8374887 Alexander Feb 2013 B1
8386070 Eliuk et al. Feb 2013 B2
8548824 daCosta Oct 2013 B1
8554579 Tribble et al. Oct 2013 B2
D693480 Spiess et al. Nov 2013 S
8595206 Ansari Nov 2013 B1
8666541 Ansari et al. Mar 2014 B1
8678047 Tribble et al. Mar 2014 B2
D715958 Bossart et al. Oct 2014 S
9053218 Osborne et al. Jun 2015 B2
D733480 Shao Jul 2015 S
D738152 Grasselli et al. Sep 2015 S
D753428 Shao Apr 2016 S
9355273 Stevens et al. May 2016 B2
9362969 Burgess et al. Jun 2016 B1
9382021 Tribble et al. Jul 2016 B2
9662273 Ranalletta et al. May 2017 B2
9930297 Alexander et al. Mar 2018 B2
9956145 Thompson et al. May 2018 B2
20050197545 Hoggle Sep 2005 A1
20060200369 Batch et al. Sep 2006 A1
20070192139 Cookson Aug 2007 A1
20070300152 Baugher Dec 2007 A1
20080046292 Myers Feb 2008 A1
20080183495 Butterfield Jul 2008 A1
20100324936 Vishnubhatla et al. Dec 2010 A1
20130197930 Garibaldi et al. Aug 2013 A1
20130304510 Chen et al. Nov 2013 A1
20140136237 Anderson et al. May 2014 A1
20140156294 Tribble et al. Jun 2014 A1
20140156298 Crawford Jun 2014 A1
20150149208 Lynch May 2015 A1
Foreign Referenced Citations (92)
Number Date Country
1516257 May 1999 CN
2440518 Aug 2001 CN
1131076 Dec 2003 CN
0237588 Sep 1987 EP
0462466 Dec 1991 EP
0505627 Sep 1992 EP
0522527 Jan 1993 EP
0439355 Sep 1994 EP
0844581 May 1998 EP
0960627 Dec 1999 EP
0970655 Jan 2000 EP
1107158 Jun 2001 EP
1097671 Feb 2003 EP
1939785 Jul 2008 EP
1939785 Jul 2008 EP
1939785 Jul 2008 EP
994977 Jun 1965 GB
2210713 Feb 1987 GB
2279784 Jan 1995 GB
2285135 Jun 1995 GB
2379037 Feb 2003 GB
3423055 Jan 1994 JP
07204253 Aug 1995 JP
2000036032 Feb 2000 JP
2002011095 Jan 2002 JP
2002092181 Mar 2002 JP
2002520718 Jul 2002 JP
2003022322 Jan 2003 JP
2004078970 Mar 2004 JP
2004326436 Nov 2004 JP
2004340770 Dec 2004 JP
2005252710 Sep 2005 JP
2006033291 Feb 2006 JP
2006334062 Dec 2006 JP
2007198934 Aug 2007 JP
2008139201 Jun 2008 JP
4276654 Jun 2009 JP
2009265827 Nov 2009 JP
2010056619 Mar 2010 JP
2010170504 Aug 2010 JP
2010533927 Oct 2010 JP
2011151430 Aug 2011 JP
2012078265 Apr 2012 JP
5342197 Nov 2013 JP
5747150 Jul 2015 JP
6086813 Mar 2017 JP
20000036642 Jul 2000 KR
1020000036642 Jul 2000 KR
20010094703 Nov 2001 KR
1020010094703 Nov 2001 KR
20050054379 Dec 2003 KR
20110115927 Oct 2011 KR
1020110115927 Oct 2011 KR
10-2013-0001500 Jan 2013 KR
10-2013-0001500 Jan 2013 KR
20130001500 Jan 2013 KR
1020130001539 Jan 2013 KR
WO8400493 Feb 1984 WO
WO9524010 Sep 1995 WO
WO9634291 Oct 1996 WO
WO9741525 Nov 1997 WO
WO9814275 Apr 1998 WO
WO9815092 Apr 1998 WO
WO9824358 Jun 1998 WO
WO9833433 Aug 1998 WO
WO9859487 Dec 1998 WO
WO9904043 Jan 1999 WO
WO9910029 Mar 1999 WO
WO9942933 Aug 1999 WO
WO9944162 Sep 1999 WO
WO9959472 Nov 1999 WO
WO0013588 Mar 2000 WO
WO0029983 May 2000 WO
WO0043941 Jul 2000 WO
WO0052437 Sep 2000 WO
WO0052626 Sep 2000 WO
WO0057339 Sep 2000 WO
WO0060449 Oct 2000 WO
WO0069331 Nov 2000 WO
WO0072181 Nov 2000 WO
WO0078374 Dec 2000 WO
WO0101305 Jan 2001 WO
WO0102979 Jan 2001 WO
WO0106468 Jan 2001 WO
WO0145774 Jun 2001 WO
WO0217777 Jul 2002 WO
WO02091276 Nov 2002 WO
WO03025826 Mar 2003 WO
WO03094073 Nov 2003 WO
WO2004070557 Aug 2004 WO
WO2004070994 Aug 2004 WO
2016003902 Jan 2016 WO
Non-Patent Literature Citations (17)
Entry
S. Suzuki and K. G. Shin, “On memory protection in real-time OS for small embedded systems,” Proceedings Fourth International Workshop on Real-Time Computing Systems and Applications, 1997, pp. 51-58, doi: 10.1109/RTCSA.1997.629173. (Year: 1997).
Extended European Search Report for related European Application No. 15815359.3; dated Dec. 2, 2018; (9 pages).
Written Opinion dated Oct. 10, 2017 issued in related Singapore Patent Application No. 11201610717W (7 Pages).
PCT/US2015/038314, International Search Report and Written Opinion of the International Searching Authority, dated Sep. 15, 2015, 12 Pages.
Singapore Written Opinion for related Singapore Application No. 11201610717W; opinion dated Aug. 14, 2018; (6 pages).
Japanese Office Action and English translation for related Japanese Application No. 2016-575743; action dated May 21, 2019; (13 pages).
Examination Report for related Australian Application No. 2015284368; action dated Feb. 20, 2020; (6 pages).
Singapore Search Report for related Singapore Application No. 11201610717W; report dated Apr. 24, 2020; (6 pages).
Australian Examination Report for related Australian Application 2015284368; report dated Aug. 20, 2020; (7 pages).
Japanese Office Action and English translation for related Japanese Application No. 2016-575743; action dated Mar. 31, 2020; (5 pages).
Examination Report for related New Zealand Application No. 727697; report dated May 5, 2021; (4 pages).
Australian Examination Report for corresponding AU Patent Application No. 2015284368, dated Jan. 21, 2021.
Extended European Search Report for related European Application No. 20203335.3; report dated Apr. 23, 2021; (15 pages).
Canadian Office action for related Canadian application No. 2,953,392; action dated Jul. 7, 2021; (5 pages).
Japanese Office Action for related Japanese Application No. 2020-130857; action dated Oct. 19, 2021; (13 pages).
Examination Report for related New Zealand Application No. 727697; report dated Nov. 29, 2021; (8 pages).
Examination Report for related Australian Application No. 2021201053; action dated Mar. 1, 2022; (6 pages).
Related Publications (1)
Number Date Country
20150379214 A1 Dec 2015 US
Provisional Applications (1)
Number Date Country
62019227 Jun 2014 US